2019

SFCR
ASR Aanvullende Ziektekostenverzekeringen N.V.
## Contents

<table>
<thead>
<tr>
<th>Introduction</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary</strong></td>
<td>8</td>
</tr>
<tr>
<td>A Business and performance</td>
<td>8</td>
</tr>
<tr>
<td>B System of governance</td>
<td>8</td>
</tr>
<tr>
<td>C Risk profile</td>
<td>9</td>
</tr>
<tr>
<td>D Valuation for Solvency purposes</td>
<td>9</td>
</tr>
<tr>
<td>E Capital management</td>
<td>10</td>
</tr>
<tr>
<td><strong>A Business and performance</strong></td>
<td>11</td>
</tr>
<tr>
<td>A.1 Business</td>
<td>11</td>
</tr>
<tr>
<td>A.1.1 Profile</td>
<td>11</td>
</tr>
<tr>
<td>A.1.2 General information</td>
<td>17</td>
</tr>
<tr>
<td>A.2 Underwriting performance</td>
<td>18</td>
</tr>
<tr>
<td>A.3 Investment performance</td>
<td>19</td>
</tr>
<tr>
<td>A.3.1 Financial assets and derivatives</td>
<td>19</td>
</tr>
<tr>
<td>A.3.2 Company statement of comprehensive income</td>
<td>20</td>
</tr>
<tr>
<td>A.3.3 Information about investments in securities</td>
<td>20</td>
</tr>
<tr>
<td>A.4 Performance of other activities</td>
<td>20</td>
</tr>
<tr>
<td>A.5 Any other information</td>
<td>20</td>
</tr>
<tr>
<td><strong>B System of governance</strong></td>
<td>21</td>
</tr>
<tr>
<td>B.1 General information on the system of governance</td>
<td>21</td>
</tr>
<tr>
<td>B.1.1 Corporate governance</td>
<td>21</td>
</tr>
<tr>
<td>B.1.2 Remuneration report</td>
<td>23</td>
</tr>
<tr>
<td>B.1.3 Remuneration of Supervisory Board and Executive Board</td>
<td>23</td>
</tr>
<tr>
<td>B.2 Fit and proper requirements</td>
<td>24</td>
</tr>
<tr>
<td>B.3 Risk management system including the Own Risk and Solvency Assessment Risk Management System</td>
<td>25</td>
</tr>
<tr>
<td>B.3.1 Risk Management Framework</td>
<td>25</td>
</tr>
<tr>
<td>B.3.2 a.s.r.’s risk categories</td>
<td>33</td>
</tr>
<tr>
<td>B.4 Internal control system</td>
<td>34</td>
</tr>
<tr>
<td>B.4.1 Strategic and operational risk management</td>
<td>34</td>
</tr>
<tr>
<td>B.4.2 Compliance function</td>
<td>36</td>
</tr>
<tr>
<td>B.5 Internal audit function</td>
<td>37</td>
</tr>
<tr>
<td>B.6 Actuarial function</td>
<td>38</td>
</tr>
<tr>
<td>B.7 Outsourcing</td>
<td>39</td>
</tr>
<tr>
<td>B.8 Any other information</td>
<td>39</td>
</tr>
<tr>
<td><strong>C Risk profile</strong></td>
<td>40</td>
</tr>
<tr>
<td>C.1 Insurance risk</td>
<td>45</td>
</tr>
<tr>
<td>C.1.1 Health insurance risk</td>
<td>45</td>
</tr>
<tr>
<td>C.1.2 Managing health insurance risk</td>
<td>46</td>
</tr>
<tr>
<td>C.2 Market risk</td>
<td>47</td>
</tr>
<tr>
<td>C.2.1 Interest rate risk</td>
<td>47</td>
</tr>
<tr>
<td>C.2.2 Equity risk</td>
<td>48</td>
</tr>
<tr>
<td>C.2.3 Property risk</td>
<td>49</td>
</tr>
<tr>
<td>C.2.4 Currency risk</td>
<td>49</td>
</tr>
<tr>
<td>C.2.5 Spread risk</td>
<td>50</td>
</tr>
<tr>
<td>C.2.6 Market risk concentrations</td>
<td>51</td>
</tr>
<tr>
<td>C.3 Counterparty default risk</td>
<td>52</td>
</tr>
<tr>
<td>C.3.1 Mortgages</td>
<td>52</td>
</tr>
<tr>
<td>C.3.2 Savings-linked mortgage loans</td>
<td>52</td>
</tr>
<tr>
<td>C.3.3 Derivatives</td>
<td>52</td>
</tr>
<tr>
<td>C.3.4 Reinsurance</td>
<td>52</td>
</tr>
<tr>
<td>C.3.5 Receivables</td>
<td>52</td>
</tr>
<tr>
<td>C.3.6 Cash and cash equivalents</td>
<td>53</td>
</tr>
<tr>
<td>C.4 Liquidity risk</td>
<td>53</td>
</tr>
<tr>
<td>C.5 Operational risk</td>
<td>54</td>
</tr>
<tr>
<td>C.6 Other material risks</td>
<td>55</td>
</tr>
<tr>
<td>C.7 Any other information</td>
<td>55</td>
</tr>
<tr>
<td>C.7.1 Description of off-balance sheet positions</td>
<td>55</td>
</tr>
<tr>
<td>C.7.2 Reinsurance policy and risk budgeting</td>
<td>55</td>
</tr>
<tr>
<td>C.7.3 Monitoring of new and existing products</td>
<td>55</td>
</tr>
<tr>
<td>C.7.4 Prudent person principle</td>
<td>55</td>
</tr>
<tr>
<td><strong>D Valuation for Solvency Purposes</strong></td>
<td>57</td>
</tr>
<tr>
<td>D.1 Assets</td>
<td>58</td>
</tr>
<tr>
<td>D.1.1 Fair value measurement</td>
<td>58</td>
</tr>
<tr>
<td>D.1.2 Assets per asset category</td>
<td>59</td>
</tr>
<tr>
<td>D.2 Technical provisions</td>
<td>61</td>
</tr>
<tr>
<td>D.2.1 Introduction</td>
<td>61</td>
</tr>
<tr>
<td>D.2.2 Technical provisions methods</td>
<td>61</td>
</tr>
<tr>
<td>D.2.3 Level of uncertainty</td>
<td>62</td>
</tr>
<tr>
<td>D.2.4 Reinsurance and special purpose vehicles (SPVs)</td>
<td>63</td>
</tr>
<tr>
<td>D.2.5 Technical provisions</td>
<td>63</td>
</tr>
<tr>
<td>D.2.6 Reconciliation between IFRS and Solvency II</td>
<td>63</td>
</tr>
<tr>
<td>D.3 Other liabilities</td>
<td>63</td>
</tr>
<tr>
<td>D.3.1 Valuation of other liabilities</td>
<td>63</td>
</tr>
<tr>
<td>D.3.2 Reconciliation from Solvency II equity to EOF</td>
<td>64</td>
</tr>
<tr>
<td>D.4 Alternative methods for valuation</td>
<td>65</td>
</tr>
<tr>
<td>D.5 Any other information</td>
<td>65</td>
</tr>
</tbody>
</table>
E  Capital management  66
E.1  Own funds  67
E.1.1  Capital management objectives  67
E.1.2  Tiering own funds  68
E.1.3  Own funds versus MCR  68
E.1.4  Description of grandfathering  69
E.2  Solvency Capital Requirement  69
E.3  Use of standard equity risk sub-module in calculation of Solvency Capital Requirement  69
E.4  Differences between Standard Formula and internal models  69
E.5  Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement  69
Introduction

The structure of the Solvency and Financial Condition Report (SFCR) has been prepared as described in annex XX of the Solvency II Directive Delegated Regulation. The subjects addressed are based on article 51 to 56 of the Solvency II Directive and act 292 up to and including 298 and act 359 of the Delegated Regulation. Furthermore, the figures presented in this report are in line with the supervisor’s reported Quantitative Reporting Templates.

All amounts in this report, including the amounts quoted in the tables, are presented in thousands of euros (€ thousand), being the functional currency of ASR Aanvullende Ziektekostenverzekeringen N.V., unless otherwise stated.
Summary

The 2019 Solvency and Financial Condition Report provides ASR Aanvullende Ziektekostenverzekeringen N.V.’s stakeholders insight in:

A Business and performance

The Solvency II ratio stood at 173% as at 31 December 2019, based on the standard formula as a result of € 24,424 thousand Eligible Own Funds and € 14,088 thousand Solvency Capital Requirement (SCR).


Full details on the ASR Aanvullende Ziektekostenverzekeringen N.V.’s business and performance are described in chapter A Business and performance (page 12).

B System of governance

This paragraph contains a description of group policy, which is applicable for the solo entity.

General
a.s.r. is a public limited company which is listed on Euronext Amsterdam and governed by Dutch corporate law. It has a two-tier board governance structure consisting of an Executive Board (EB) and a Supervisory Board (SB). The EB is responsible for the realisation of corporate objectives, the strategy with its associated risks and the delivery of the results. The SB is responsible for advising the EB, supervising its policies and the general state of affairs relating to a.s.r. and its group entities. As of 1 February 2019 a.s.r. changed its management structure. This was effected through the appointment of a Business Executive Committee (BEC). The BEC works alongside the EB and shares responsibility for the implementation of the business strategy.

Risk management
It is of great importance to a.s.r. that risks within all business lines are timely and adequately controlled. In order to do so, a.s.r. has implemented a Risk Management framework based on internationally recognized and accepted standards (such as COSO ERM and ISO 31000:2018 risk management principles and guidelines). Using this framework, material risks that a.s.r. is, or can be, exposed to, are identified, measured, managed, monitored and evaluated. The framework is applicable to a.s.r. group, ASR Aanvullende Ziektekostenverzekeringen N.V. and other underlying business entities.

Control environment
In addition to risk management, a.s.r.’s Solvency II control environment consist of an internal control system, an actuarial function, a compliance function, and an internal audit function. The system of internal control includes the management of risks at different levels in the organisation, both operational and strategic. Internal control at an operational level centres around identifying and managing risks within the critical processes that pose a threat to the achievement of the business line’s objectives. The actuarial function is responsible for expressing an opinion on the adequacy and reliability of reported technical provisions, reinsurance and underwriting. The mission of the compliance function is to enhance and ensure a controlled and sound business operation where impeccable, professional conduct is self-evident. The Audit Department evaluates the effectiveness of governance, risk management and internal control processes, and gives practical advice on process optimisation.

Full details on the Aanvullende Ziektekostenverzekeringen N.V.’s system of governance are described in chapter B System of governance (page 21).
C Risk profile

ASR Aanvullende Ziektekostenverzekeringen N.V. applies an integrated approach in managing risks, ensuring that our strategic goals (customer interests, financial solidity and efficiency of processes) are maintained. This integrated approach ensures that value will be created by identifying the right balance between risk and return, while ensuring that obligations towards our stakeholders are met. Risk management supports ASR Aanvullende Ziektekostenverzekeringen N.V. in the identification, measurement and management of risks and monitors to ensure adequate and immediate actions are taken in the event of changes in ASR Aanvullende Ziektekostenverzekeringen N.V.’s risk profile.

ASR Aanvullende Ziektekostenverzekeringen N.V. is exposed to the following types of risks: market risk, counterparty default risk, insurance risk, strategic risk and operational risk. The risk appetite is formulated at both group and legal entity level and establishes a framework that supports an effective selection of risks.

The solvency capital requirement is build up as follows:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th></th>
<th></th>
<th>2018</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Market</td>
<td>1,681</td>
<td></td>
<td></td>
<td>1,814</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance</td>
<td>12,221</td>
<td>-1,441</td>
<td>-935</td>
<td>11,503</td>
<td>202</td>
<td>-1,377</td>
</tr>
<tr>
<td>Counterparty</td>
<td>399</td>
<td></td>
<td></td>
<td>-892</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operational</td>
<td>2,163</td>
<td></td>
<td></td>
<td>2,175</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diversification</td>
<td>-1,441</td>
<td>-935</td>
<td></td>
<td>-1,377</td>
<td>-892</td>
<td></td>
</tr>
<tr>
<td>SCR</td>
<td>14,088</td>
<td></td>
<td></td>
<td>13,425</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Full details on the ASR Aanvullende Ziektekostenverzekeringen N.V.’s risk profile are described in chapter C Risk profile (page 40).

D Valuation for Solvency purposes

ASR Aanvullende Ziektekostenverzekeringen N.V. values its Solvency II balance sheet items on a basis that reflects their economic value. Where the IFRS fair value is consistent with Solvency II requirements, ASR Aanvullende Ziektekostenverzekeringen N.V. follows IFRS for valuing assets and liabilities other than technical provisions.

The reconciliation of IFRS equity and Excess Assets over Liabilities (Solvency II basis) can be summarized as follows:
- derecognition of items on the Solvency II economic balance sheet which are admissible on the IFRS balance sheet,
- for instance goodwill, pre-paid commissions and other intangible assets;
- revaluation differences on mainly insurance liabilities and other assets which are valued other than fair value in the IFRS balance sheet.

To reconcile from Solvency II equity to EOF, the following movements are taken into consideration:
- subordinated liabilities: in accordance with the Delegated Regulation the subordinated liabilities are part of the EOF.
A graphical representation of the reconciliation from Solvency II equity to EOF is presented below:

**Reconciliation total equity IFRS vs EOF Solvency II**

<table>
<thead>
<tr>
<th>IFRS Equity</th>
<th>Adjustment</th>
<th>Total net revaluations</th>
<th>Other revaluations</th>
<th>Own fund items</th>
<th>Eligible own funds Solvency II</th>
</tr>
</thead>
<tbody>
<tr>
<td>18,717</td>
<td>0</td>
<td>5,707</td>
<td>0</td>
<td>0</td>
<td>24,424</td>
</tr>
</tbody>
</table>

Full details on the reconciliation between ASR Aanvullende Ziektekostenverzekeringen N.V.’s economic balance sheet based on Solvency II and consolidated financial statements based on IFRS are described in chapter D Valuation for solvency purposes (page 56).

**E Capital management**

Overall capital management is administered at group level. Capital generated by operating units and future capital releases will be allocated to profitable growth of new business or repatriated to shareholders, beyond the capital that is needed to achieve management’s targets.

ASR Aanvullende Ziektekostenverzekeringen N.V. has no internal model and follows the default method for the determination of the group solvency. ASR Aanvullende Ziektekostenverzekeringen N.V. maintains an internal minimum and management target for the Solvency II ratio. The internal minimum Solvency II ratio for ASR Aanvullende Ziektekostenverzekeringen N.V. as formulated in the risk appetite statement is 110%. The management threshold level for the Solvency II ratio is above 150%. a.s.r. only distributes cash dividends if the interest of the policyholders has been ensured (i.e. a Solvency II ratio above 130%). The Solvency II ratio was 173% at 31 December 2019.
The EOF are build up as follows:

**Eligible own fund**

<table>
<thead>
<tr>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1 capital - unrestricted</td>
<td>24,424</td>
</tr>
<tr>
<td>Tier 1 capital - restricted</td>
<td></td>
</tr>
<tr>
<td>Tier 2 capital</td>
<td></td>
</tr>
<tr>
<td>Tier 3 capital</td>
<td></td>
</tr>
<tr>
<td>Eligible own funds to meet SCR</td>
<td>24,424</td>
</tr>
</tbody>
</table>

ASR Aanvullende Ziektekostenverzekeringen N.V. has formulated its dividend policy in line with its current strategy. ASR Aanvullende Ziektekostenverzekeringen N.V. intends to pay an annual dividend that creates sustainable long-term value for its shareholders. ASR Aanvullende Ziektekostenverzekeringen N.V. aims to operate at a solvency ratio, calculated according to the standard formula, above the management threshold level of 150%.

Full details on the capital management of ASR Aanvullende Ziektekostenverzekeringen N.V. can be found in chapter E Capital Management (page 65).
A Business and performance

A.1 Business

A.1.1 Profile

Object of the company
ASR Aanvullende Ziektekostenverzekeringen N.V. provides supplementary insurance to healthcare insurance under the Dutch Healthcare Insurance Act.

ASR Aanvullende Ziektekostenverzekeringen N.V. aims to promote the health of its customers and improve healthcare. ASR Aanvullende Ziektekostenverzekeringen N.V. focuses on client satisfaction and profitable growth of the customer base. We do this by offering quality products, excellent service, a good price and visible and valued brands.

Core activities
The core activity of ASR Aanvullende Ziektekostenverzekeringen N.V. is the provision of supplementary insurance to basic health insurance under the Dutch Healthcare Insurance Act. The number of insured persons of ASR Aanvullende Ziektekostenverzekeringen N.V. amounted to 319,403 in 2019.

In 2019, the healthcare market was served by a.s.r. from two labels: De Amersfoortse and Ditzo. De Amersfoortse focuses mainly on smaller entrepreneurs (SMEs), employees and self-employed workers without employees. Distribution takes place via the intermediary channel. Ditzo focuses exclusively via the direct online channel on price-conscious customers who wish to have adequate cover for additional risks.

In-house healthcare procurement
Given that it considers the health of its customers as one of its core focus areas, a.s.r. ended the outsourcing of healthcare procurement in 2017 and started in 2018 to bring the contracting of healthcare providers in-house. This was continued in 2019. With the switch to in-house healthcare procurement, a.s.r. health aims to strengthen its relationship with healthcare providers for the benefit of its customers, while at the same time facilitating smooth declaration processes in order to benefit customers and healthcare providers alike.

Legal structure of the company
ASR Aanvullende Ziektekostenverzekeringen N.V. is a wholly-owned subsidiary of ASR Ziektekostenverzekeringen N.V., which in turn is a wholly-owned subsidiary of ASR Nederland N.V. (a.s.r.). a.s.r. is a public limited company under Dutch law having its registered office located at Archimedeslaan 10, 3584 BA in Utrecht, the Netherlands. a.s.r. has chosen the Netherlands as ‘country of origin’ (land van herkomst) for the issued share capital and corporate bonds which are listed on Euronext Amsterdam and the Irish Stock Exchange. (Ticker: ASRNL).”

Internal organisational structure
In 2019, the organisation of ASR Aanvullende Ziektekostenverzekeringen N.V. was divided into the following segments: Operations and Information Management, Health, Customer and Finance. Operations includes Client Acceptance, Health Declarations and Receivables Management. Information Management includes the Data team, Health Project Management and the Health Service Chain. Health can be subdivided into the Medical Advice Group, Procurement and Policy & Advisory Bureau. Customer Health consists of the Contact Centre team and supporting functions. The segment Finance includes Health Control, Business Risk Management and team Finance.
Organizational chart
Below, the organizational chart of ASR Aanvullende Ziektekostenverzekeringen N.V. is presented:

Organisational chart:

- Ziektekosten
  - Health
    - Procurement
    - Medical Advice Group
    - Policy and Advisory Bureau
  - Customer Health
    - Contact Centre Team
    - Supporting Functions
  - Finance, Risk & Health Control
    - Business Risk Management
    - Health Control
    - Business Control
    - Business Actuarial
  - Operations and Information Management
    - Health Project Management
    - Health Service Chain
    - Data Team
    - Client Acceptance
    - Receivables Management
    - Health Declarations
Headcount
All employees are employed by a.s.r. The a.s.r. employees work for ASR Basis Ziektekostenverzekeringen N.V. (a.s.r. Ziektekosten basis) as well as ASR Aanvullende Ziektekostenverzekeringen N.V. and ASR Wlz-uitvoerder B.V. In 2019, a.s.r. Health employed an average of 176 (2018: 180) internal employees. In addition, a flexible layer was used, mostly during November/December, when new business was acquired. Specific teams were supported by temporary external employees.

The Executive Board consists of J.D. Lansberg and J.M. Hendriks. The composition of the Executive Board remained unchanged in 2019.

The composition of the Supervisory Board of ASR Aanvullende Ziektekostenverzekeringen N.V. is as follows: C. van der Pol (Chairman), S. Barendregt (acceded on 22 May 2019) and J.P.M. Baeten. Michel Verwoest resigned as a member of the Supervisory Board on 1 February 2019. A.P. Aris resigned as a member of the Supervisory Board on 22 May 2019.

Key elements of the policy
In line with a.s.r.’s mission statement of ‘helping by doing’, the strategy of ASR Aanvullende Ziektekostenverzekeringen N.V. is to improve our customer’s health. It therefore provides information, services and products to customers in the hope that this helps them in improving their condition and general health. The introduction of a.s.r. Vitality, available for all health insurance customers, is an example of the execution of its mission.

Given that it considers the health of its customers as one of its core areas, a.s.r. ended the outsourcing of healthcare procurement in 2017 and started to bring the contracting of healthcare providers in-house in 2018. This continued in 2019.

With the switch to in-house healthcare procurement, a.s.r. aims to strengthen its relationship with healthcare providers for the benefit of its customers, while at the same time facilitating smooth declaration processes in order to benefit both customers and healthcare providers.

ASR Aanvullende Ziektekostenverzekeringen N.V. aims to increase customer satisfaction by organising an efficient and client-focused customer service process. ASR Aanvullende Ziektekostenverzekeringen N.V. puts considerable effort into streamlining and digitising the process of paying declarations, customer onboarding and other services, thereby leading to faster and more accurate payments to customers, lower operating costs and efficient processes. Furthermore, ASR Aanvullende Ziektekostenverzekeringen N.V. prides itself in continuously improving client interaction, and serving customers at the time and manner chosen by them. ASR Aanvullende Ziektekostenverzekeringen N.V. continuously updates the practical information it provides to its employees so that they can in turn improve the quality, accuracy and speed of the information they give to customers. All of these resulted in increased customer satisfaction of 43 in 2019.

NPS Health

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>39</td>
<td>43</td>
</tr>
</tbody>
</table>

Target: 45

a.s.r. puts significant time and effort in evaluating and developing its high-quality products and services. In 2019, both Ditzo and De Amersfoortse launched a new type of basic health insurance policy; an in-kind policy (naturapolis) which is the most common kind of policy in the Dutch market; 75% of the insured population have an in-kind policy. An in-kind policy is also called contracted care. If an insured person visits a contracted care provider, the healthcare costs will be reimbursed. If they visit a non-contracted care provider, they will have to pay part of the healthcare costs, usually around 20-30%. Increasing sales of basic health insurance policies likely increase the sale of additional insurance policies.

De Amersfoortse introduced a new proposition; Zorg voor Ondernemers (health for entrepreneurs). This proposition is made for entrepreneurs, including self-employed persons without a disability insurance. The proposition aims to reduce the risk of (physical) ailments by providing coverage, services and help to support entrepreneurs in staying healthy and productive before – or as soon as – ailments appear.
Market and distribution developments

Market developments
The health insurance market is a highly regulated market. All Dutch residents are obliged to have basic health insurance coverage. Basic coverage is the same across all insurers, since it is a statutory requirement. Although supplementary insurance coverage is not obligated, 84% of the market chose a form of supplementary health insurance in 2019. Health insurance contracts are taken out for a year at the time. At 6-7%, the percentage of customers that switch between health insurance providers per calendar year has been relatively stable over the past four years. In 2019, the percentage of customers that switched was 7%.

The general trend to accept all persons by insurers continued in 2019. Consumers increasingly specifically select additional packages for the healthcare they expect to need. As a result, they choose less or no additional products.

Internal control of processes and procedures
For ASR Aanvullende Ziektekostenverzekeringen N.V. adequate risk management is essential to control the quality of processes and procedures and for continuous operational improvements. This results in, among other things, increased customer satisfaction reflected in the Net Promotor Score (NPS).

Risk appetite statements are in place to manage the business within the risk profile limits. The Business Risk Committee (BRC) monitors (on an ongoing basis) and discusses (on a quarterly basis) whether non-financial risks are adequately managed. If a risk profile exceeds the appetite, the BRC agrees on actions to be taken.

ASR Aanvullende Ziektekostenverzekeringen N.V. performs comprehensive risk management to increase financial robustness. Therefore insight into the size and the potential interconnectedness of risks enables ASR Aanvullende Ziektekostenverzekeringen N.V. to accept risks that are responsible and consistent with the associated reward.

In 2019 ASR Aanvullende Ziektekostenverzekeringen N.V. improved the effectiveness of its operational risk control framework based on a risk-based approach. A Comprehensive Risk Management Framework makes sure that ASR Aanvullende Ziektekostenverzekeringen N.V. management has impact on its overall risk profile and facilitates responsible risk management. The key risks and key controls are annually identified, defined and evaluated by the ASR Aanvullende Ziektekostenverzekeringen N.V. management. The effectiveness of key control measures is tested periodically.

In addition to the activities mentioned above, ASR Aanvullende Ziektekostenverzekeringen N.V. risk management is also sustained by performing the Strategic Risk Analysis (SRA), the Own Risk and Solvency Assessments (ORSA), operational incidents monitoring and project risk assessments. New products and services and accompanying customer brochures undergo an internal ‘Product Approval and Review Process (PARP)’.

In 2019, ASR Aanvullende Ziektekostenverzekeringen N.V. completed various actions to enhance the measurement and reporting of data quality for financial reporting purposes and to mitigate the end-user computing risks. During this year the procedure related to operational incidents has been improved and is embedded within the organisation.

Quality control
ASR Aanvullende Ziektekostenverzekeringen N.V wants to be the most personal health insurer offering its customers an excellent service. The foundation for this is quality management. Quality management contains policies, guidelines and principles on how ASR Aanvullende Ziektekostenverzekeringen N.V. wants to serve its customers. The standards laid down in the quality policy are the starting point in actively complying with the quality standards for customer-oriented insurance, continuous improvement of processes within all departments and providing training to employees.

In order to actively steer towards the objectives, they have been translated into key performance indicators (KPIs). The progress and results on these KPIs are periodically shared within ASR Aanvullende Ziektekostenverzekeringen N.V.

ASR Aanvullende Ziektekostenverzekeringen N.V attaches great importance to feedback from its customers. That is why, in 2019, continuous feedback was requested by means of NPS on both customer contact (contact measurement) and the handling of complaints (process measurement). ASR Aanvullende Ziektekostenverzekeringen N.V. also measures the customer satisfaction of customers who used social media. This gave ASR Aanvullende Ziektekostenverzekeringen N.V. an even better insight into what customers think of its information provision, services, First Time Right and the quality of its customer contact in general. The feedback was used to improve processes and train employees.
Also uses ASR Aanvullende Ziektekostenverzekeringen N.V. the Customer Effort Score (CES) to get an insight in how much effort the customers must deliver, for example when submitting an invoice. The results of this study had given ASR Aanvullende Ziektekostenverzekeringen N.V. input for improvements.

The ambition in terms of service provision to customers is reflected in an increase in the NPS from +39 (overall score for our Customer Contact over 2018) to +43 over 2019.

In 2019, ASR Aanvullende Ziektekostenverzekeringen N.V. continued the roll-out of the new customer contact strategy. This is aimed at enabling customers to contact us efficiently and effectively in the way and at the moment that suits them best. To this end, additional research was carried out by means of a customer panel and an extensive data analysis was carried out that gives us a good insight of how customers use the various channels.

In 2019 we saw a decrease in the number of complaints in comparison with 2018. The number of complaints has decreased from 1,456 in 2018 to 1,320 in 2019. The main reasons for this decrease are that we have improved the support for customer care employees who treat complaints. Next to that we have improved the operational performance what has resulted in a lower number of complaints.

In 2018 we started with the mapping of the total customer journey and in 2019 we translated this to a digital customer journey framework. This will give us further insights about when and how customers contact us, how they appreciate this and where we can improve our processes.

**Finance**

Overall capital management is administered at group level. a.s.r. currently plans to consider investing capital above the Solvency II ratio (calculated based on the standard formula) of 160% (management threshold level) with the objective of creating value for its shareholders. If and when a.s.r. operates at a level considerably above the management threshold level and it believes that it cannot invest this capital in value-creating opportunities for a prolonged period of time, it may decide to return (part of this) capital to shareholders. If a.s.r. chooses to return capital, it plans to do so in a form that is efficient for shareholders at that time. a.s.r. actively manages its in-force business, which is expected to result in free capital generation over time. Additionally, business improvement and balance sheet restructuring should improve the capital generation capacity while advancing the risk profile of the company. ASR Aanvullende Ziektekostenverzekeringen N.V. is capitalised separately. Excess capital over management’s targets and not allocated to profitable growth of new business or other strategic goals, can be used for example to repay earlier capital investments to the extent local regulations allow and within the internal risk appetite statement. Due to the growth of the portfolio in 2020 a subordinated loan was received bij a.s.r. Basis Ziektekostenverzekeringen N.V., which was financed by a dividend upstream from ASR Aanvullende Ziektekostenverzekering N.V. N.V. of € 9 million at year end.
A.1.2 General information
The SFCR has been prepared by and is the sole responsibility of the Company’s management. Selected Own Funds and SCR information are also reported in ASR Aanvullend Ziektekostenverzekeringen N.V financial statements. EY has examined the 2019 financial statements and issued an unqualified audit report thereon.

Name and contact details of the supervisory authority
Name: De Nederlandsche Bank
Visiting address: Westeinde 1, 1017 ZN Amsterdam
Phone number (general): +31 800 020 1068
Phone number (business purposes): +31 20 524 9111
Email: info@dnb.nl

Name and contact details of the external auditor
Name: EY
Visiting address: Cross Towers,
Antonio Vivaldisstraat 150,
1083 HP Amsterdam
Phone number: +31 88 407 1000
A.2 Underwriting performance

Key figures
- The net result amounted to € 3.2 million (2018: € 2.5 million);
- Gross written premiums decreased to € 72.1 million (2018: € 72.5 million);
- Operating costs decreased by 12.1% to € 6.7 million (2018: € 7.6 million);
- Combined ratio improved to 94.0 % (2018: 94.5%).

<table>
<thead>
<tr>
<th>Key figures ASR Aanvullende Ziektekostenverzekeringen N.V.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(in € thousands, unless stated otherwise)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Gross premiums written</td>
</tr>
<tr>
<td>Operating expenses</td>
</tr>
<tr>
<td>Profit before tax</td>
</tr>
<tr>
<td>Income tax (expense) / gain</td>
</tr>
<tr>
<td>Profit for the year</td>
</tr>
<tr>
<td>New business</td>
</tr>
<tr>
<td>Combined ratio</td>
</tr>
<tr>
<td>Claims ratio</td>
</tr>
<tr>
<td>Commission ratio</td>
</tr>
<tr>
<td>Expense ratio</td>
</tr>
</tbody>
</table>

Gross new business
Gross written premiums saw a slight decline in 2019 compared to 2018 despite a shrinking of the portfolio. This is mainly caused by the premium increase in 2019.

Operating expenses
Operating expenses amounted to € 6.7 million (2018: € 7.6 million). The decrease is mainly due to a decrease in operational costs following tight cost control by implementing a reorganisation in the second half of 2018. In addition, the consultancy costs are lower as a result of cooperation with the Innovation & Digital department of a.s.r. resulting in lower direct project expenses.

Gross new business
Gross new business in 2019 amounted to € 5 million, a decrease of 14.2% compared to last year. ASR Aanvullende Ziektekostenverzekeringen N.V. showed shrinkage in the number of insured persons in 2019. The decline of the portfolio is the result of the offered premium in the basic insurance, which was higher than its competitors.

Profit/(loss) for the year
The net result for 2019 was € 3.2 million, an increase of € 0.6 million compared to 2018. The main reason are the lower operating and social plan costs as explained above, tempered by the increase in acquisition costs due to the increase in health insurance contracts sold for 2020.

Combined ratio
The combined ratio decreased compared to last year. The claims ratio decreased due to the better pricing of the products in 2019. The calculated behavior of the insured persons had been taken into account during the calculation of the premiums. The operating expenses already explain above. The commission ratio increased due to higher cost per acquisition. The cost of acquisition are higher due to growth in the portfolio in 2020.

Solvency and liquidity on balance sheet date
Overall capital management is administered at group level. The legal entities are capitalised separately. For ASR Aanvullende Ziektekostenverzekeringen N.V. no upstreaming of capital or dividend to the group level is currently foreseen. All capital present is used for strengthening of the capital positioning, investments or to maintain a socially responsible pricing level.
The solvency ratio stood at 173% at 31 December 2019 (2018: 196%), which was higher than the management target of above 150%. Due to the growth of the portfolio in 2020 a subordinated loan was received bij ASR Basis Ziektekostenverzekeringen N.V., which was financed by a dividend upstream from ASR Aanvullende Ziektekostenverzekeringen N.V. of €9 million at year end.

A.3 Investment performance

ASR Aanvullende Ziektekostenverzekeringen N.V.’s investment policy is aimed at striking a balance between generating returns and preventing risks. Protecting the solvency position is an important factor in this context.

A.3.1 Financial assets and derivatives

<table>
<thead>
<tr>
<th>Investments</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Available for sale</td>
<td>29,408</td>
<td>39,351</td>
</tr>
<tr>
<td>Total investments</td>
<td>29,408</td>
<td>39,351</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Breakdown of investments available for sale</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
</tr>
<tr>
<td>Fixed income investments</td>
</tr>
<tr>
<td>Government bonds</td>
</tr>
<tr>
<td>Corporate bonds</td>
</tr>
<tr>
<td>Equities and similar investments</td>
</tr>
<tr>
<td>Equities</td>
</tr>
<tr>
<td>Total investments available for sale</td>
</tr>
</tbody>
</table>

Based on their contractual maturity, an amount of €20 million (2018: €33 million) of fixed income is expected to be recovered after one year after the balance sheet date. For assets without a contractual maturity date, it is expected that they will be recovered after more than one year after the balance sheet date.

Investment income

<table>
<thead>
<tr>
<th>Breakdown of investment income per category</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
</tr>
<tr>
<td>Interest income from investments</td>
</tr>
<tr>
<td>Other interest income</td>
</tr>
<tr>
<td>Interest income</td>
</tr>
<tr>
<td>Dividend on equities</td>
</tr>
<tr>
<td>Dividend and other investment income</td>
</tr>
<tr>
<td>Total investment income</td>
</tr>
</tbody>
</table>

The effective interest method has been applied to an amount of €47 thousand (2018: €128 thousand) of the interest income from financial assets not classified at fair value through profit or loss.
A.3.2 Company statement of comprehensive income

<table>
<thead>
<tr>
<th>Company statement of comprehensive income for the year ended 31 December</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit for the year</td>
<td>3,163</td>
<td>2,515</td>
</tr>
<tr>
<td>Unrealised change in value of available for sale assets</td>
<td>783</td>
<td>-869</td>
</tr>
<tr>
<td>Realised gains/(losses) on available for sale assets reclassified to profit or loss</td>
<td>-24</td>
<td>-110</td>
</tr>
<tr>
<td>Income tax on items that may be reclassified subsequently to profit or loss</td>
<td>-183</td>
<td>249</td>
</tr>
<tr>
<td><strong>Total items that may be reclassified subsequently to profit or loss</strong></td>
<td><strong>575</strong></td>
<td><strong>-730</strong></td>
</tr>
<tr>
<td><strong>Total other comprehensive income for the year, after tax</strong></td>
<td><strong>575</strong></td>
<td><strong>-730</strong></td>
</tr>
<tr>
<td><strong>Total comprehensive income</strong></td>
<td><strong>3,738</strong></td>
<td><strong>1,785</strong></td>
</tr>
</tbody>
</table>

A.3.3 Information about investments in securities
As ASR Aanvullende Ziektekostenverzekeringen N.V. has no investments in securitization, no further information is included here.

A.4 Performance of other activities
No other activities are material.

A.5 Any other information
No other information is applicable.
B System of governance

In the case where the text below refers to ‘the company’, ASR Aanvullende Ziektekostenverzekeringen N.V. is meant.

B.1 General information on the system of governance

B.1.1 Corporate governance

ASR Aanvullende Ziektekostenverzekeringen N.V. has an Executive Board (EB) and a Supervisory Board (SB).

Executive Board
The EB is responsible for the company’s management, meaning that it is responsible for aspects such as achieving corporate objectives, the strategy and the associated risk profile, and the ensuing financial performance of the company and its subsidiaries.

The General Meeting of Shareholders appoints the members of the EB and may suspend or dismiss any member of the EB at any time. The SB may also suspend any member of the EB. A suspension by the SB may be initiated by the General Meeting of Shareholders at any time. a.s.r. aims to have an adequate and balanced composition of the EB. The EB consists of two members, one woman and one man. In 2017, the SB adopted a formal diversity policy. a.s.r. uses the following definition for diversity: a balanced composition of the workforce, based on age, gender, cultural or social origin, competences, views and working styles. One of the objectives is an EB consisting of at least 30% women and at least 30% men. The current composition of the EB does meet both goals regarding the gender balance of the EB.

Supervisory Board
The SB is responsible for overseeing, checking (also proactively) and advising the EB with regard to achieving the corporate objectives, the strategy and the risks associated with the company’s business activities. The SB consists of three members (2018: four members). The General Meeting of Shareholders appoints the members of the SB and may suspend or dismiss any member of the SB at any time.

This paragraph contains a description of group policy, which is applicable for ASR Aanvullende Ziektekostenverzekeringen N.V. ASR Aanvullende Ziektekostenverzekeringen N.V. has its own governance structure, which is described below. ASR Aanvullende Ziektekostenverzekeringen N.V. uses the facilities of the group and has its own EB and SB.

B.1.1.1 Supervisory Board Committees

Audit and Risk Committee
The SB did not institute an Audit and Risk Committee. Audit and risk issues are discussed during a separate part of every meeting of the SB in the presence of the senior management of the Audit, Risk and Compliance departments.

Remuneration Committee
The SB did not institute a Remuneration Committee.

Selection & Appointment Committee
The SB did not institute a Selection, Appointment and Remuneration Committee.

B.1.1.2 Corporate Governance

ASR Aanvullende Ziektekostenverzekeringen N.V. is a limited liability company. The company has a two-tier board; a SB and an EB. The General Meeting of Shareholders is authorized to appoint and dismiss members of the EB and the SB.

B.1.1.3 Executive Board
The EB is responsible for the day-to-day conduct of business of ASR Aanvullende Ziektekostenverzekeringen N.V. and for the strategy, structure and performance. In performing their duties the EB is guided by ASR Aanvullende Ziektekostenverzekeringen N.V.’s interests, which include the interests of the business connected with ASR Aanvullende Ziektekostenverzekeringen N.V., which, in turn, include the interests of customers, insurers, employees and, in general, the society in which ASR Aanvullende Ziektekostenverzekeringen N.V.’s business is carried out. The EB is accountable for the performance of its duties to the SB and to the General Meeting.
Composition
The EB will consist of a minimum of two members. The General Meeting of Shareholders appoints the EB members and may at any time suspend or dismiss any member of the EB. Only candidates found to meet the fit and proper test under the Dutch Financial Markets Supervision Act are eligible for appointment. The EB consists of J.M. Hendriks and J.D. Lansberg. The composition of the EB remained unchanged in 2019.

Education and evaluation Executive Board of the group
The members of the EB followed individual programs in 2019 as part of their continuing education (CE). In addition, much attention was devoted to knowledge-development in the areas of risk, capital management and strategic challenges, including the impact of political decisions on the potential business models of health care insurers in The Netherlands.

The decision making process of the EB was self-evaluated in 2019 and discussed with the deputy directors. Goal of the evaluation and discussion was to find useful elements and ways to further enhance the effective decision-making and information gathering. In addition to the self-evaluation, the performance of the members of the EB was also assessed by the SB.

B.1.1.4 Supervisory Board
The SB supervises the policy pursued by the EB and the general course of affairs at ASR Aanvullende Ziektekostenverzekeringen N.V. and advises the EB. Specific powers are vested in the SB, including the approval of certain decisions taken by the EB.

Composition
The SB of ASR Aanvullende Ziektekostenverzekeringen N.V. consists of three members: C. van der Pol (chairman), J.P.M. Baeten and S. Barendregt. The SB has drawn up a profile for its size and composition, taking into account the nature of ASR Aanvullende Ziektekostenverzekeringen N.V.’s business, its activities and the desired expertise and background of the SB members.

The composition of the SB is such that each supervisory director should have the skills to assess the main aspects of the overall policy and that the SB as a whole meets the profile thanks to a combination of the experience, expertise and independence of the individual supervisory directors. The SB is diverse in terms of the gender and professional background of its members. The diversity of its members ensures the complementary profile of the SB.

Education and evaluation Supervisory Board of the group
The SB is responsible for assessing the quality of its own performance. It therefore performs an annual self-assessment and discussion of its own performance and that of its committees and members. A self-assessment with external supervision is carried out every three years. The self-assessment for 2019 was carried out with internal guidance. The assessment was based on written and oral input from the members of the SB, the EB and the Company Secretary. The following aspects were assessed:
• Composition and functioning of the SB (strengths and points for improvement);
• Effectiveness of processes (information-gathering and decision-making);
• Advisory role;
• Role as an employer.

The outcome of the assessment was discussed in a formal meeting of the SB with the EB. The overall impression that emerged from this self-assessment was positive. The SB is seen as a properly operating group in terms of content, with a balanced and high-quality composition. The atmosphere is open and the relationship with the EB is good. One recommendation made was to improve an open dialogue on relevant strategic issues at an early stage to strengthen the role as advisor of the board.

In 2019, specific sessions were organised for the benefit of further education. The first session was a follow-up on the explanation of IFRS 17, the new accounting standard for insurance contracts, led by Finance, Risk & Performance Management. The new regulations will impact future external reporting on insurance contracts. The implementation of IFRS 17 within a.s.r. is a major project. The second session focused on Investment Management. This knowledge session was led by a.s.r. Asset Management and took place at the end of the year. During this session, the SB were given an update on strategic investment management, Artificial Intelligence (AI) and robotisation in investment management, economic development and the strategic vision for 2020.

The individual members were given updates and presentations on various topics in view of their supervisory directorships at several Dutch and foreign enterprises and institutions.
B.1.1.5 Corporate Governance Codes and regulations

Dutch Health Insurers Code Code
ASR Aanvullende Ziektekostenverzekeringen is subject to the Dutch Health Insurers Code (2012). This code contains principles for governance. Specifically, it defines guidelines for the fulfilment of the public responsibility regarding the execution of the compulsory Dutch Health Insurance Act. Every year, ASR Aanvullende Ziektekostenverzekeringen N.V. accounts its performance to the Dutch Healthcare Authority.

Professional oath
On 1 January 2013, the Dutch financial sector introduced a mandatory oath for EB and SB members of financial institutions licensed in the Netherlands. With regard to insurance companies, in addition to the EB and SB members, individuals holding a management position immediately below the EB who are responsible for staff who may have a significant influence on the risk profile of the insurance company, are also required to take the oath, as are certain other employees. This includes individuals who may (independently) significantly influence the risk profile of the undertaking as well as those who are or may be involved in the provision of financial services.

Notwithstanding the above, a.s.r. has decided that all employees and other individuals carrying out activities under its responsibility must take the oath. New employees must take the oath within three months of joining the company.

B.1.2 Related-party transactions
A related party is a person or entity that has significant influence over another entity, or has the ability to affect the financial and operating policies of the other party. Parties related to ASR Aanvullende Ziektekostenverzekeringen N.V. include a.s.r. and its subsidiaries, members of the EB, members of the SB, close family members of any person referred to above, entities controlled or significantly influenced by any person referred to above and any other affiliated entity.

ASR Aanvullende Ziektekostenverzekeringen N.V. regularly enters into transactions with related parties during the conduct of its business. These transactions mainly involve loans and receivables, subordinated liabilities and allocated expenses, and are conducted on terms equivalent to those that prevail in arm’s length transactions.

- The remuneration of the EB and SB of ASR Aanvullende Ziektekostenverzekeringen N.V. are described in chapter B.1.4;
- The operating expenses are predominantly intercompany, consisting of allocated expenses from head office, support functions and expenses related to personnel;
- Transactions with a.s.r. concern the payment of taxes as a.s.r. heads the fiscal unity.

Positions and transactions between ASR Aanvullende Ziektekostenverzekeringen N.V. and the related parties

Financial scope of a.s.r.’s related party transactions

<table>
<thead>
<tr>
<th>Balance sheet items with related parties as at 31 December</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subordinated liabilities</td>
<td>0</td>
<td>4.992</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>4.553</td>
<td>4.826</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transactions in the income statement for the financial year</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest income</td>
<td>117</td>
<td>51</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>30</td>
<td>37</td>
</tr>
<tr>
<td>Interest expenses</td>
<td>1</td>
<td>199</td>
</tr>
</tbody>
</table>

The subordinated liability was fully repaid at arm’s length during the year.

No provisions for impairments have been recognised on the loans and receivables for the years 2019 and 2018. No loans were provided by ASR Aanvullende Ziektekostenverzekeringen N.V. to the EB.

B.1.3 Remuneration of Supervisory Board and Executive Board
The remuneration policy of the EB and SB members is determined in accordance with the current Articles of Association of ASR Nederland N.V.
B.1.3.2 Remuneration of current and former Executive Board members

The remuneration of current and former members is in accordance with the 2019 remuneration policy.

The EB of a.s.r. ziektekosten basis is also the EB of ASR Aanvullende Ziektekostenverzekeringen N.V. The total costs of the EB is allocated for 73.14% (2018: 72.14%) to a.s.r. ziektekosten basis and 26.86% (2018: 27.86%) to ASR Aanvullende Ziektekostenverzekeringen N.V. The applicable WNT maximum is calculated accordingly. In the table below the allocated cost to a.s.r. ziektekosten basis are presented.

### Annual remuneration for members of the a.s.r. Executive Board

<table>
<thead>
<tr>
<th>Executive Board member</th>
<th>Fixed employee benefits</th>
<th>Pension benefits</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>drs. J.M. Hendriks RA⁶</td>
<td>50</td>
<td>7</td>
<td>57</td>
</tr>
<tr>
<td>drs. J.D. Lansberg⁷</td>
<td>65</td>
<td>9</td>
<td>74</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>115</strong></td>
<td><strong>16</strong></td>
<td><strong>131</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Executive Board member</th>
<th>Fixed employee benefits</th>
<th>Pension benefits</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>drs. J.M. Hendriks RA⁶</td>
<td>49</td>
<td>10</td>
<td>59</td>
</tr>
<tr>
<td>drs. J.D. Lansberg⁷</td>
<td>69</td>
<td>10</td>
<td>79</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>118</strong></td>
<td><strong>20</strong></td>
<td><strong>138</strong></td>
</tr>
</tbody>
</table>

The EB are employed by a.s.r. The remuneration recognised amounts to the costs charged from a.s.r. to ASR Aanvullende Ziektekostenverzekeringen N.V. for the fulfilment of the function of EB member at ASR Aanvullende Ziektekostenverzekeringen N.V. The costs charged consist of wage costs including employer’s social security costs and any lease car costs.

B.2 Fit and proper requirements

a.s.r. has a policy that sets out principles and criteria to ensure that persons who effectively run the undertaking and other key functions are fit and proper. The fit and proper policy provides guidance on the assessment process and contributes to controlled and sound business operations and promotes the stability and integrity of a.s.r. as well as customer confidence. a.s.r. assesses all prospective employees (internal and external FTE’s) for their reliability and integrity prior to their appointment.

---

1. C. van der Pol was member of the Supervisory Board from 1 January 2019 until 31 December 2019.
2. A.P. Aris was member of the Supervisory Board from 1 January 2019 until 22 May 2019.
3. J.P.M. Baeten was member of the Supervisory Board from 1 January 2019 until 31 December 2019.
4. S. Barendregt was member of the Supervisory Board from 22 May 2019 until 31 December 2019.
5. M.H. Verwoest was member of the Supervisory Board from 1 January 2019 until 1 February 2019.
6. Member of the Executive Board since 1 April 2015.
7. Member of the Executive Board since 1 September 2016.
The fit and proper requirements that are imposed on persons who effectively run the undertaking and other key functions are included in the job profile, which is used as a basis for recruitment. Each year, an assessment is made of the extent to which an employee may require additional training. In addition, a.s.r. has a program for the continuing education of persons who effectively run the undertaking and other key functions.

B.3 Risk management system including the Own Risk and Solvency Assessment Risk Management System

This paragraph contains a description of group policy, which is applicable for the solo entity. It is of great importance to a.s.r. that risks within all business lines are timely and adequately controlled. In order to do so, a.s.r. implemented a Risk Management framework based on internationally recognized and accepted standards (such as COSO ERM and ISO 31000:2018 risk management principles and guidelines). Using this framework, material risks that a.s.r. is, or can be, exposed to, are identified, measured, managed, monitored and evaluated. The framework is both applicable to a.s.r. group and the underlying (legal) business entities.

B.3.1 Risk Management Framework

The figure below is the risk management framework as applied by a.s.r.

Risk Management Framework

The Risk Management (RM) framework consists of risk strategy (including risk appetite), risk governance, systems and data, risk policies and procedures, risk culture, and risk management process. The RM framework contributes to achieving the strategic, tactical and operational objectives as set out by a.s.r.

Risk strategy (incl. risk appetite)
Risk strategy is defined to contain at least the following elements:
- Strategic objectives that are pursued;
- The risk appetite in pursuit of those strategic objectives.

a.s.r.’s risk strategy aims to ensure that decisions are made within the boundaries of the risk appetite, as stipulated annually by the Executive Board (EB) and the Supervisory Board (SB) (see chapter B.3.1.1 Risk strategy and risk appetite).

Risk governance
Risk governance can be seen as the way in which risks are managed, through a sound risk governance structure and clear tasks and responsibilities, including risk ownership. a.s.r. employs a risk governance framework that entails the tasks and responsibilities of the risk management organisation and the structure of the Risk committees (see chapter B.3.1.2 Risk governance).
Systems and data
Systems and data support the risk management process and provide management information to the risk committees and other relevant bodies. a.s.r. finds it very important to have qualitatively adequate data, models and systems in place, in order to be able to report and steer correct figures and to apply risk-mitigating measures timely. To ensure this, a.s.r. has designed a policy for data quality and model validation in line with Solvency II. Tools, models and systems are implemented to support the risk management process by giving guidance to and insights into the key risk indicators, risk tolerance levels, boundaries and actions, and remediation plans to mitigate risks (see chapter B.3.1.3 Systems and data).

Risk policies and procedures:
Risk policies and procedures at least:
• Define the risk categories and the methods to measure the risks;
• Outline how each relevant category, risk area and any potential aggregation of risk is managed;
• Describe the connection with the overall solvency needs assessment as identified in the Own Risk & Solvency Assessment (ORSA), the regulatory capital requirements and the risk tolerances;
• Provide specific risk tolerances and limits within all relevant risk categories in line with the risk appetite statements;
• Describe the frequency and content of regular stress tests and the circumstances that would warrant ad-hoc stress tests.

The classification of risks within a.s.r. is performed in line with, but is not limited to, the Solvency II risks. Each risk category consists of a policy that explicates how risks are identified, measured and controlled within a.s.r. (see chapter B.3.1.4 Risk policies and procedures).

Risk culture
An effective risk culture is one that enables and rewards individuals and groups for taking risks in an informed manner. It is a term describing the values, beliefs, knowledge, attitudes and understanding about risk. All the elements of the RM framework combined make an effective risk culture.

Within a.s.r. risk culture is an important element that emphasizes the human side of risk management. The EB has a distinguished role in expressing the appropriate norms and values (tone at the top). a.s.r. employs several measures to increase the risk awareness and, in doing so, the risk culture (see chapter B.3.1.5 Risk culture).

Risk management process
The risk management process contains all activities within the RM processes to structurally 1) identify risks; 2) measure risks; 3) manage risks; 4) monitor and report on risks; and 5) evaluate the risk profile and risk management framework. At a.s.r., the risk management process is used to implement the risk strategy in the steps mentioned. These five steps are applicable to the risks within the company to be managed effectively (see chapter B.3.1.6 Risk Management process).

B.3.1.1 Risk management strategy and risk appetite
This paragraph discusses the risk appetite of ASR Aanvullende Ziektekostenverzekeringen N.V. and is derived from the policy document Capital and Dividend Policy of ASR Basis Ziektekostenverzekeringen N.V. and ASR Aanvullende Ziektekostenverzekeringen N.V.

ASR Aanvullende Ziektekostenverzekeringen N.V. belongs to the insurance group a.s.r. Nederland. a.s.r. Nederland has a capital and dividend policy that enables the group to steer towards the financial stability of the group in a structured and balanced manner. Under the articles of association, ASR Aanvullende Ziektekostenverzekeringen N.V. has its own responsibility for the capital position. A (limited) transition is therefore necessary in order to make the capital policy of the umbrella group applicable to ASR Aanvullende Ziektekostenverzekeringen N.V. As far as possible, these choices are made in line with the policy of a.s.r. Nederland.

The aim of this policy is to establish a stable, consistent and predictable policy for the management of capital within ASR Aanvullende Ziektekostenverzekeringen N.V. in order to promote the company’s stability and continuity so as to meet the obligations towards policyholders at all times.

Each year, specific objectives (management target) and risk limits (risk appetite) for the capital position of ASR Aanvullende Ziektekostenverzekeringen N.V are set by the Executive Board, with the approval of the Supervisory Board. A solvency objective (management target) reflects the level of solvency sought and contains a reasonable buffer above the internal limits of the risk appetite statement. The difference between the limits of the risk appetite statement and the objectives (management target) is that a limit is very strict and that breaking a limit will have to be remedied immediately, whereas an objective is a long-term target value.

B.3.1.1 Substantiation and structure of limits and objectives for the solvency of a.s.r.
The objectives and limits are set annually by the EB of ASR Aanvullende Ziektekostenverzekeringen N.V. based on the principles for capital management as laid down in the capital policy. Under certain circumstances, and with the approval of the SB of ASR Aanvullende Ziektekostenverzekeringen N.V., substantiated deviations from these principles may be made.

The objectives and limits are agreed with the EB and the SB of a.s.r. Nederland in order to ensure the consistency of the capital policy within the group. Of course, this working method does not affect the personal responsibility of the ASR Aanvullende Ziektekostenverzekeringen N.V. EB members under the articles of association.

B.3.1.2 Risk governance
a.s.r.’s risk governance can be described by:
- Risk ownership;
- the implemented three lines of defence model and associated (clear delimitation of) tasks and responsibilities of key function holders; and
- the risk committee structure to ensure adequate decision making.

Risk ownership
The EB has the final responsibility for risk exposures and management within the organization. Part of the responsibilities have been delegated to persons that manage the divisions where the actual risk-taking takes place. Risk owners are accountable for one or more risk exposures that are inextricably linked to the department or product line they are responsible for. Through the risk committee structure, risk owners provide accountability for the risk exposures.

Three lines of defence
The risk governance structure is based on the ‘three lines of defence’ model. The ‘three lines of defence’ model consists of three defence lines with different responsibilities with respect to the ownership of controlling risks. The model below provides insight in the organization of the three lines of defence within a.s.r.

Three lines of defence model

<table>
<thead>
<tr>
<th>First line of defence</th>
<th>Second line of defence</th>
<th>Third line of defence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Board</td>
<td>Group Risk Management</td>
<td>Audit department</td>
</tr>
<tr>
<td>Management teams of</td>
<td>department</td>
<td>- Internal audit function</td>
</tr>
<tr>
<td>the business lines and</td>
<td>- Risk management function</td>
<td></td>
</tr>
<tr>
<td>their employees</td>
<td>- Actuarial function</td>
<td></td>
</tr>
<tr>
<td>Finance &amp; risk decentral</td>
<td>Integrity department</td>
<td>- Compliance function</td>
</tr>
<tr>
<td>Ownership and</td>
<td>Policies and monitoring</td>
<td>Independent assessment</td>
</tr>
<tr>
<td>implementation</td>
<td>implementation by 1st line</td>
<td>of 1st and 2nd lines</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ownership and</td>
<td>Policies and monitoring</td>
<td>Policies and monitoring</td>
</tr>
<tr>
<td>implementation</td>
<td>implementation by 1st line</td>
<td>implementing policies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and objectives in accordance with the risk appetite</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Has sufficient countervailing power to prevent risk concentrations and other forms of excessive risk taking</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Responsible for developing risk policies and monitoring the compliance with these policies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Responsible for providing dedicated assurance services and oversees and assesses the functioning and the effectiveness of the first two lines of defence</td>
</tr>
</tbody>
</table>
**Positioning of key functions**

Within the risk governance, the key functions (compliance, risk, actuarial and audit) are organized in accordance with Solvency II regulation. They play an important role as countervailing power of management in the decision-making process. The four key functions are independently positioned within a.s.r. In all the risk committees one or more key functions participate. None of the functions has voting rights in the committees, in order to remain fully independent as countervailing power. All functions have direct communication lines with the EB and can escalate to the chairman of the Audit & Risk Committee of the SB. Furthermore, the key functions have regular meetings with the supervisors of the Dutch Central Bank (DNB) and/or The Dutch Authority for the Financial Markets (AFM).

**Group Risk Management**

Group Risk Management (GRM) is responsible for the execution of the risk management function (RMF) and the actuarial function (AF). The department is led by the CRO. GRM consists of the following sub-departments:
- Enterprise Risk Management;
- Financial Risk Management (including AF).

**Enterprise Risk Management**

Enterprise Risk Management (ERM) is responsible for second-line operational (including IT) risk management and the enhancement of the risk awareness for a.s.r. and its subsidiaries. The responsibilities of ERM include the development of risk policies, the annual review and update of the risk strategy (risk appetite), the coordination of the SRA process leading to the risk priorities and ORSA scenarios and the monitoring of the non-financial risk profile. For the management of operational risks, a.s.r. has a solid Risk-Control framework in place that contributes to its long-term solidity. The RMF monitors and reviews the non-financial strategic and operational risk profile. The quality of the framework is continuously enhanced by the analysis of operational incidents, periodic risk assessments and monitoring by the RMF. ERM actively promotes risk awareness at all levels to contribute to the vision of staying a socially relevant insurer.

**Financial Risk Management**

Financial Risk Management (FRM) is responsible for the second line financial risk management and supports both the AF and RMF. An important task of FRM is to be the countervailing power to the EB and management in managing financial risks for a.s.r. and its subsidiaries. FRM assesses the accuracy and reliability of the market risk, counterparty risk, insurance risk and liquidity risk, risk margin and best estimate liability. Other responsibilities are model validation and policies on valuation and risk. FRM is also responsible for the actuarial function. As part of the AF, FRM reviews the technical provisions, monitors methodologies, assumptions and models used in these calculations, and assesses the adequacy and quality of data used in the calculations. Furthermore, the AF expresses an opinion on the underwriting policy and determines if risks related to the profitability of new products are sufficiently addressed in the product development process. The AF also expresses an opinion on the adequacy of reinsurance arrangements.

**Compliance**

Compliance is responsible for the execution of the compliance function. An important task of Compliance is to be the countervailing power to the EB and other management in managing compliance risks for a.s.r. and its subsidiaries. The mission of the compliance function is to enhance and ensure controlled and sound business operations where impeccable, professional conduct is self-evident.

As second line of defence, Compliance encourages the organization to comply with relevant rules and regulations, ethical standards and the internal standards derived from them (‘rules’) by providing advice and devising policies. Compliance supports the first line in the identification of compliance risks and assesses the effectiveness of risk management on which Compliance reports to the relevant risk committees. In doing so, Compliance uses a compliance risk and monitoring framework. In line with risk management, Compliance also creates further awareness in order to promote a culture of integrity. Compliance coordinates contacts with regulators in order to maintain an effective relationship and keeps oversight of the current topics.

**Audit**

The Audit department, the third line of defence, provides an independent opinion on governance, risk and management processes, with the goal of supporting the EB and other management of a.s.r. in achieving the corporate objectives. To that end, Audit evaluates the effectiveness of governance, risk and management processes, and provides pragmatic advice that can be implemented to further optimize these processes. In addition, senior management can engage Audit for specific advisory projects.

**Risk committee structure**

a.s.r. has established a structure of risk committees with the objective to monitor the risk profile for a.s.r. group, its legal entities and its business lines in order to ensure that it remains within the risk appetite and the underlying risk tolerances
and risk limits. When triggers are hit or likely to be hit, risk committees make decisions regarding measures to be taken, being risk-mitigating measures or measures regarding governance, such as the frequency of their meetings. For each of the risk committees a statute is drawn up in which the tasks, composition and responsibilities of the committee are defined.

ASR Aanvullende Ziektekostenverzekeringen N.V. uses the risk infrastructure of the Group (see below), and in addition has its own business risk committee. Both operational and financial risk are in scope of this committee.

**Risk committee structure**

**Audit & Risk Committee**
The Audit & Risk Committee was established by the Supervisory Board to gain support, among other things, in the following matters:
- Assessment of the risk appetite proposal and quarterly monitoring of the risk profile
- Assessment of the annual report, including the financial statements of ASR Nederland N.V.;
- The relationship with the independent external auditor, including the assessment of the quality and independence of the independent external auditor and the proposal by the SB to the AGM to appoint the independent external auditor;
- The performance of the audit function, compliance function, the actuarial function and the risk management function;
- Compliance with rules and regulations; and
- The financial position.

The Audit & Risk Committee has three members of the SB, one of whom acts as the chairman.

**Business Executive Committee – Risk meeting**
The Business Executive Committee – Risk meeting (BEC – Risk meeting) monitors a.s.r.’s overall risk profile on a quarterly basis. At least annually, the BEC – Risk meeting determines the risk appetite statements, limits and targets for a.s.r. This relates to the overall a.s.r. risk appetite and the subdivision of risk appetite by financial and non-financial risks. The risk appetite is then submitted to the a.s.r. Audit & Risk Committee, which advises the SB on the approval of the risk appetite. The BEC – Risk meeting also monitors the progress made in managing risks included in the Risk Priorities of the EB.

All members of the EB participate in the BEC – Risk meeting, which is chaired by the CEO. The involvement of the EB ensures that risk decisions are being addressed at the appropriate level within the organization. In addition to the EB,
the Key Functions (Risk management, Compliance, Internal audit, Actuarial function) are members of the Committee. In addition, it consists of a number of senior managers who present a number of focus areas.

Non-Financial Risk Committee
The Non-Financial Risk Committee (NFRC) discusses, advises and decides upon non-financial risk policies. The most relevant risk policies are approved by the BEC – Risk meeting. The NFRC monitors that non-financial risks are managed adequately and monitors that the risk profile stays within the agreed risk limits. If the risk profile exceeds the limits, the NFRC takes mitigating actions. The NFRC reports to the BEC – Risk meeting. The NFRC is chaired by a member of the EB.

Financial Risk Committee
The Financial Risk Committee (FRC) discusses and decides upon financial risk policies. The most relevant financial risk policies are approved by the BEC – Risk meeting. The FRC monitors and controls financial risks (market, insurance (life and non-life) and counterparty default risk). The FRC also monitors whether the risk profile stays within the risk limits. If the risk profile exceeds these limits, the FRC takes mitigating actions. The FRC reports to the BEC – Risk meeting. The Chairman of the FRC is the CFO.

Capital, Liquidity and Funding Committee
The Capital, Liquidity and Funding Committee (CLFC) is a subcommittee of the FRC. As such, the CLFC prepares and assesses the technical analysis of capital, liquidity and funding positions, rating policy, rating model reporting, and treasury activities. The Chairman of the CLFC is the Director of Group Asset Management.

Model Validation Committee
The model validation committee (MVC) is a subcommittee of the FRC and is responsible for the execution and update of the model validation policy and the approval of validation of existing or newly developed models. The MVC receives all required information for the validation of models (e.g. model documentation and validation reports) prepared by the validation board (MVB) that assures the quality of the validation process. The chairman of the MVC is the CRO.

Business Risk Committees
The business lines manage and control their risk profile through the Business Risk Committees (BRC). The BRC’s monitor that the risk profile of the business lines stays within the risk appetite, limits and targets, as formulated by the EB. The BRC reports to the FRC and the NFRC. The Chairman of the BRC is the Managing Director of the business line.

Central Investment Committee
In addition to the risk committee structure, the Central Investment Committee (CIC) monitors tactical decisions and the execution of the investment policy. It takes investment decisions within the boundaries of the strategic asset allocation as agreed upon in the FRC. The CIC bears particular responsibility for investment decisions exceeding the mandate of the investment department. The CIC is chaired by the Director of Group Balance Sheet Management (GBSM).

Product Approval and Review Process Board
The Product Approval & Review Process Board (PARP Board) is responsible for the final decision-making process around the introduction of new products and adjustments in existing products. The committee evaluates if potential risks in newly developed products are sufficiently addressed. New products need to be developed in such a way that they are cost efficient, reliable, useful and secure. New products also need to have a strategic fit with a.s.r.’s mission to be a solid and trustful insurer. In addition, the risks of existing products are evaluated, as requested by the product approval and review process as a result of product reviews. The PARP Board is chaired by the managing Director of the business line Health.

B.3.1.3 Systems and data
GRC tooling is implemented to support the risk management process by giving guidance and insight into the key risk indicators, risk tolerance levels, boundaries and actions and remediation plans to mitigate risks. The availability, adequacy and quality of data and IT systems is important in order to ensure that correct figures are reported and risk mitigating measures can be taken in time. It is important to establish under which conditions the management information that is submitted to the risk committees has been prepared and which quality safeguards were applied in the process of creating this information. This allows the risk committees to ascertain whether the information is sufficient to base further decisions upon.
a.s.r. has a Data Governance and Quality policy in place to support the availability of correct management information. This policy is evaluated on an annual basis and revised at least every three years to keep the standards in line with the latest developments on information management. The quality of the information is reviewed based on the following aspects, based on Solvency II:

• completeness (including documentation of accuracy of results);
• adequacy;
• reliability;
• timeliness.

The preparatory body or department checks the assumptions made and the plausibility of the results, and ensures coordination with relevant parties. When a preparatory body has established that the information is reliable and complete, it approves and formally submits the document(s) to a risk committee.

The information involved tends to be sensitive. To prevent unauthorized persons from accessing it, it is disseminated using a secure channel or protected files. a.s.r.’s information security policy contains guidelines in this respect.

a.s.r.’s information security policy is based on ISO 27002 ‘Code of practice for information security management’. This Code describes best practices for the implementation of information security.

The aim of the information security policy is to take measures to ensure that the requirements regarding availability, reliability and integer and confidential use of systems and data are met.

• Information availability refers to the degree to which the information is at hand as soon as the organization needs it, meaning, for instance, that the information should be retrievable on demand and that it can be consulted and used at the right time;
• The integrity, i.e. reliability, of information is the degree to which it is up-to-date, complete and error-free;
• ‘Confidential use’ refers to the degree to which the information is available to authorized persons only and the extent to which it is not available to unauthorized persons.

There are technical solutions for accomplishing this, by enforcing a layered approach (defence-in-depth) of technical measures to avoid unauthorized persons (i.e. hackers) to compromise a.s.r. corporate data and systems. In this perspective, one may think of methods of logical access management, intrusion detection techniques, in combination with firewalls are aimed at preventing hackers and other unauthorized persons from accessing information stored on a.s.r. systems. Nevertheless, confidential information can also have been committed to paper. In addition to technical measures there are physical measures and measures that helps the right awareness of personnel as part of the information security environment.

When user defined models (e.g. spreadsheets) are used for supporting the RM Framework, the ‘a.s.r. Standard for End user computing’- in addition to the general security policy - defines and describes best practices in order to guard the reliability and confidentiality of these tools and models. a.s.r. recognizes the importance of sound data quality and information management systems.

The management of IT and data risks of the implemented tools, models and systems (including data) is part of the Operational IT risk management.

B.3.1.4 Risk policies and procedures

a.s.r. has established guidelines, including policies that cover all main risk categories (market, counterparty default, liquidity, underwriting, strategic and operational). These policies address the accountabilities and responsibilities regarding management of the different risk types. Furthermore, the methodology for risk measurement is included in the policies. The content of the policies is aligned to create a consistent and complete set. The risk policy landscape is maintained by Group Risk Management and Compliance. These departments also monitor the proper implementation of the policies in the business. New risk policies or updates of existing risk policies are approved by the risk committees as mentioned previously.

B.3.1.5 Risk culture

Risk awareness is a vital component of building a sound risk culture within a.s.r. that emphasizes the human aspect in the management of risks. In addition to gaining sufficient knowledge, skills, capabilities and experience in risk management, it is essential that an organization enables objective and transparent risk reporting in order to manage them more effectively.

The EB clearly recognizes the importance of risk management and is therefore represented in all of the major group level risk committees. Risk Management is involved in the strategic decision-making process, where the company’s risk appetite
is always considered. The awareness of risks during decision-making is continually addressed when making business
decisions, for example by discussing and reviewing risk scenarios and the positive and/or negative impact of risks before
finalizing decisions.

It is very important that this risk awareness trickles down to all parts of the organization, and therefore management
actively encourages personnel to be aware of risks during their tasks and projects, in order to avoid risks or mitigate them
when required. The execution of risk analyses is embedded in daily business in, for example, projects, product design and
outsourcing.

In doing so, a.s.r. aims to create a solid risk culture in which ethical values, desired behaviours and understanding of risk in
the entity are fully embedded. Integrity is of the utmost importance at a.s.r.: this is translated into a code of conduct and
strict application policies for new and existing personnel, such as taking an oath or promise when entering the company,
and the ‘fit and proper’ aspect of the Solvency II regulation, ensuring that a.s.r. is overseen and managed in a professional
manner.

Furthermore, a.s.r. believes it is important that a culture is created in which risks can be discussed openly and where
risks are not merely perceived to be negative and highlight that risks can also present a.s.r. with opportunities. Risk
Management (both centralized and decentralized) is positioned as such, that it can communicate and report on risks
independently and transparently, which also contributes to creating a proper risk culture.

B.3.1.6 Risk management process
The risk management process typically comprises of five important steps: 1) identifying; 2) measuring; 3) managing; 4)
monitoring and reporting; and 5) evaluating. a.s.r. has defined a procedure for performing risk analyses and standards for
specific assessments. The five different steps are explained in this chapter.

Identifying
Management should endeavour to identify all possible risks that may impact the strategic objectives of a.s.r., ranging from
the larger and/or more significant risks posed on the overall business, down to the smaller risks associated with individual
projects or smaller business lines. Risk identification comprises of the process of identifying and describing risk sources,
events, and the causes and effects of those events.

Measuring
After risks have been identified, quantitative or qualitative assessments of these risks take place to estimate the likelihood
and impact associated with them. Methods applicable to the assessment of risks are:
• Sensitivity analysis;
• Stress testing;
• Scenario analysis;
• Expert judgments (regarding likelihood and impact); and
• Portfolio analysis.

Managing
Typically, there are five strategies to managing risk:
• Accept: risk acceptance means accepting that a risk might have consequences, without taking any further mitigating
  measures;
• Avoid: risk avoidance is the elimination of activities that cause the risk;
• Transfer: risk transference is transferring the impact of the risk to a third party;
• Mitigate: risk mitigation involves the mitigation of the risk likelihood and/or impact;
• Exploit: risk exploitation revolves around the maximization of the risk likelihood and/or increasing the impact if the risk
does happen.

Risk management strategies are chosen in a way that ensures that a.s.r. remains within the risk appetite tolerance levels
and limits.

Monitoring and reporting
The risk identification process is not a continuous exercise. Therefore, risk monitoring and reporting are required to
capture changes in environments and conditions. This also means that risk management strategies could, or perhaps
should, be adapted in accordance with risk appetite tolerance levels and limits.

1 Based on COSO ERM and ISO 31000.
Evaluating
The evaluation step is twofold. On the one hand, evaluation means risk exposures are evaluated against risk appetite tolerance levels and limits, taking (the effectiveness of) existing mitigation measures into account. The outcome of the evaluation could lead to a decision regarding further mitigating measures or changes in risk management strategies. On the other hand, the risk management framework (including the risk management processes) is evaluated by the risk management function, in order to continuously improve the effectiveness of the risk management framework as a whole.

B.3.2 a.s.r.’s risk categories
a.s.r. is exposed to a variety of risks. There are six main risk categories that a.s.r. recognises, as described below. These descriptions are based on a.s.r. level, not all risks are applicable for ASR Aanvullende Ziektekostenverzekering N.V.

Insurance risk
Insurance risk is the risk that premium and/or investment income or outstanding reserves will not be sufficient to cover current or future payment obligations, due to the application of inaccurate technical or other assumptions and principles when developing and pricing products. a.s.r. recognises the following insurance risk:
- Life insurance risk
- Health insurance risk
- Non-life insurance risk

Market risk
The risk of changes in values caused by market prices or volatility of market prices differing from their expected values. The following types of market risk are distinguished:
- Interest rate risk
- Equity risk
- Property risk
- Spread risk
- Currency risk
- Concentration risk/market concentration risk

Counterparty default risk
Counterparty default risk is the risk of losses due to the unexpected failure to pay or credit rating downgrade of counterparties and debtors. Counterparty default risk exists in respect of the following counterparties:
- Reinsurers
- Consumers
- Intermediaries
- Counterparties that offer cash facilities
- Counterparties with which derivatives contracts have been concluded
- Healthcare providers
- Zorginstituut Nederland

Liquidity risk
Liquidity risk is the risk that a.s.r. is not able to meet its financial obligations to policyholders and other creditors when they become due and payable, at a reasonable cost and in a timely manner.

Operational risk
Operational risk is the risk of losses caused by weak or failing internal procedures, weaknesses in the action taken by personnel, weaknesses in systems or because of external events. The following subcategories of operational risk are used:
- Compliance
- Business process
- Financial reporting
- Outsourcing
- Information technology
- Project risks

Strategic risk
Strategic risk is the risk of a.s.r. or its business lines failing to achieve the objectives due to incorrect decision-making, incorrect implementation and/or an inadequate response to changes in the environment. Such changes may anse in the following areas:
- Climate
- Demographics
Strategic risk may arise due to a mismatch between two or more of the following components: the objectives (resulting from the strategy), the resources used to achieve the objectives, the quality of implementation, the economic climate and/or the market in which a.s.r. and/or its business lines operate.

B.4 Internal control system

This paragraph contains a description of group policy, which is applicable for ASR Aanvullende Ziektekostenverzekeringen N.V. Within a.s.r., internal control is defined as the processes, affected by the board of directors, senior management, and other personnel within the organisation, implemented to obtain a reasonable level of certainty with regard to achieving the following objectives:

- High-level goals, aligned with and supporting the organisation’s mission
- Effective and efficient use of resources
- Reliability of operational and financial reporting
- Compliance with applicable laws regulations and ethical standards
- Safeguarding of company assets

B.4.1 Strategic and operational risk management

The system of internal control includes the management of risks at different levels in the organisation, both operational and strategic.

B.4.1.1 Strategic Risk Management

Strategic risk management aims to identify and manage the most significant risks that may impact a.s.r.’s strategic objectives. Subsequently, the aim is to identify and analyse the risk profile as a whole, including risk interdependencies.

The ORSA process is designed to identify, measure, manage and evaluate those risks that are of strategic importance to a.s.r.:

**Identifying**

Through the ORSA process, identification of risks is structurally organized through the combined top-down and bottom-up SRA approach. The SRA outcomes are jointly translated into risk scenarios and ‘risk priorities’, in which the most significant risks for a.s.r. are represented.

**Measuring**

Through the ORSA process, the likelihood and impact of the identified risks are assessed, taking into account (the effectiveness of) risk mitigating measures and planned improvement actions. Information from other processes1 is used to gain additional insights into the likelihood and impact. One single risk scenario takes multiple risks into account. In this manner, the risk scenarios provide (further) insights into risk interdependencies.

**Managing**

As part of the SRA processes, the effectiveness of risk mitigating measures and planned measures of improvement is assessed. This means risk management strategies are discussed, resulting in refined risk management strategies.

**Monitoring and reporting**

The output of the ORSA process is translated into day-to-day risk management and monitoring and reporting, both at group level and product line levels. At group level, the risk priorities are discussed on a quarterly basis in the BEC – Risk meeting. At the level of the product lines, risks are discussed in the BRC’s.

1 For example, the SAA-study, analyses in the context of reinsurance renewals, ad hoc sensitivity analyses and/or stress tests.
Evaluating
Insights regarding likelihood and impact are evaluated against solvency targets. Based on this evaluation, conclusions are formulated regarding the adequacy of solvency objectives at group and individual legal entity level.

B.4.1.2 Operational Risk Management
Operational Risk Management (ORM) involves the management of all possible risks that may influence the achievement of the business goals and that can cause financial or reputational damage. ORM includes the identification, analysis, prioritization and management of these risks in line with the risk appetite. The policy on ORM is drafted and periodically evaluated under the coordination of ERM. The policy is implemented in the decentralized business entities under the responsibility of the management boards. A variety of risks is covered by ORM policy: IT risk, outsourcing, data quality, project, underwriting etc.

Identifying
With the operational targets as a starting point, each business entity performs risk assessments to identify events that could influence these targets. In each business entity the business risk manager facilitates the periodic identification of the key operational risks. All business processes are taken into account to identify the risks. All identified risks are prioritized and recorded in a risk-control framework.

The risk policies prescribe specific risk analyses to be performed to identify and analyse the risks. For important IT systems, Information Security Analyses (IVA – Informatie Veiligheids Analyse) have to be performed and for large outsourcing projects a specific risk analysis is required.

Measuring
All risks in the risk-control frameworks are assessed on likelihood of defaults and impact. Where applicable, the variables are quantified, but often judgments of subject matter experts are required. Based on the estimation of the variables, each risk is labelled with a specific level of concern (1 to 4). Gross risks with a level of concern 3 or 4 are considered ‘key’.

Managing
For each risk, identified controls are implemented into the processes to keep the level of risk within the agreed risk appetite (level of concern 1 or 2). In general, risks can be accepted, mitigated, avoided or transferred. A large range of options is available to mitigate operational risks, depending on the type. An estimation is made of the net risk, after implementing the control(s).

Monitoring and reporting
The effectiveness of operational risk management is periodically monitored by the business risk manager at each business line or legal entity. For each key control in the risk-control framework a testing calendar is established, based on accounting standards. Each control is tested regularly and the outcomes of the effectiveness of the management of key risks are reported to the management board. Outcomes are also reported to the NFRC and BEC – Risk meeting.

Evaluating
Periodically, yet at least annually, the risk-control frameworks and ORM policies are evaluated to see if revisions are necessary. The risk management function also challenges the business lines and legal entities regarding their risk-control frameworks.

Operational incidents
Operational incidents are reported to GRM, in accordance with the operational risk policy. The causes of losses are evaluated in order to learn from these experiences. An overview of the largest operational incidents and the level of operational losses is reported to the NFRC. Actions are defined and implemented to avoid repetition of operational losses.

ICT
Through IT risk management, a.s.r. devotes attention to the efficiency, effectiveness and integrity of ICT, including End User Computing applications. The logical access control for key applications used in the financial reporting process remains a high priority in order to enhance the integrity of applications of data. The logical access control procedures also prevent fraud by improving segregation of duties and by conducting regular checks of actual access levels within the applications. Proper understanding of information, security and cyber risks is essential, reason for which continuous actions are carried out to create awareness among employees and management.
**Business Continuity Management**

Operational management can be disrupted significantly by unforeseen circumstances or calamities which could ultimately disrupt the execution of critical and operational processes. Business Continuity Management enables a.s.r. to continue its daily business uninterruptedly and to react quickly and effectively during such situations.

Critical processes and activities and the tools necessary to use for these processes are identified during the Business Impact Analysis. This includes the resources required to establish similar activities at a remote location. The factors that can threaten the availability of those tools necessary for the critical processes are identified in the Threat Analysis.

a.s.r. considers something a crisis when one or more business lines are (in danger of being) disrupted in the operational management, due to a calamity, or when there is a reputational threat. In order to reduce the impact of the crisis, to stabilize the crisis, and to be able to react timely, efficiently and effectively, a.s.r. has assigned a crisis organization.

There is a central crisis team led by member of the board. Each business line has their own crisis team led by the director of the management team. The continuity of activities and the recovery systems supporting critical activities are regularly tested and crisis teams are trained annually. The objective of the training is to give the teams insights into how they function during emergencies and to help them perform their duties more effectively during such situations. The training also sets out to clarify the roles, duties and responsibilities of the crisis teams. One important training scenario used is a scenario that includes cyber threats.

**Preparatory Crisis Plan**

On 1 January 2019 new legislation entered into force that addresses the recovery and settlement of insurance companies ("Wet herstel en afwikkeling van verzekeraars" in Dutch). The objective is that insurance companies and supervisors are better prepared against a crisis and that insurance companies can recover from a crisis without government aid. a.s.r. is obliged to have a Preparatory Crisis Plan ("Voorbereidend Crisisplan" in Dutch) in place that has been approved by De Nederlandsche Bank (DNB). a.s.r.’s Preparatory Crisis Plan helps to be prepared and have the capacity to act in various forms of extreme financial stress. The Preparatory Crisis Plan describes and quantifies the measures that can be applied to live through a crisis situation. These measures are tested in the scenario analysis, in which the effects of each recovery measure on a.s.r.’s financial position (solvency and liquidity) are quantified. The required preparations for implementing the measures, their implementation time and effectiveness, potential obstacles, impact on policy holders and operational effects are also assessed. The main purpose of the Preparatory Crisis Plan is to increase the chances of successful early intervention in the event of a financial crisis situation and to further guarantee that the interest of policyholders and other stakeholders are protected.

**Reasonable assurance and model validation**

a.s.r. aims to obtain reasonable assurance regarding the adequacy and accuracy of the outcomes of models that are used to provide best estimate values and solvency capital requirements. To this end, multiple instruments are applied, including model validation. Materiality is determined by means of an assessment of impact and complexity. Impact and complexity is expressed in terms of High (H), Medium (M), or Low (L).

In the pursuit of reasonable assurance, model risk is mitigated and unacceptable deviations are avoided, against acceptable costs.

**B.4.2 Compliance function**

This paragraph contains a description of group policy, which is applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

The mission of the Compliance function is to enhance and ensure a controlled and sound business operation where impeccable professional conduct is self-evident.

**Positioning and structure of the compliance function**

The Compliance function is a centralised function which is headed by the a.s.r. Compliance Manager for both a.s.r. and the supervised entities. The compliance function, the second line of defence, is considered a key function in line with the Solvency II regulation. The CEO bears ultimate responsibility for the compliance function and the a.s.r. compliance manager has a direct reporting line and access to him. The a.s.r. compliance manager also has an escalation line to the Chairman of the a.s.r. Audit & Risk Committee and/or the Chairman of the SB in order to safeguard the independent position of the compliance function and enable it to operate autonomously. The a.s.r. compliance manager is entitled to scale up critical compliance matters to the highest organisational level or to the SB.
Responsibilities and duties
The Compliance function, as part of the second line of defense, is responsible for:
• Encouraging compliance with relevant rules and regulations, ethical standards and the internal standards derived from them (rules) by providing advice and formulating policies;
• Monitoring compliance with rules;
• Monitoring the management of compliance risks by further developing adequate compliance risk management, including monitoring and, where necessary, making arrangements relating to measures and actions;
• Creating awareness of the need to comply with rules and of social and ethical issues, in which ethical behavior within a.s.r. is self-evident;
• Coordinating contacts with regulators in order to maintain effective and transparent relationships with them.

Annual compliance plan
Developments in rules and the management of high compliance risks and action plans provide the basis for the annual compliance plans and the compliance monitoring activities. a.s.r. continuously monitors changing legislation and regulations and assesses their impact and corresponding actions to be taken. In 2019, Compliance largely realised its annual compliance plan as planned. Various monitoring activities were performed on group and division level. Compliance monitored compliance with the CDD regulation, the IDD regulation, the outsourcing policy (in cooperation with the group risk management department) and the quality of information provided to customers. The Compliance department played a central role in a.s.r.’s CDD optimization project. In order to guarantee sound and controlled business operations, a.s.r. has taken a number of control measures to prevent, identify and combat unethical behavior, including corruption.

Reporting
The a.s.r. Compliance Manager issues quarterly reports on compliance matters and the progress made in the relevant actions at Group level, supervised entity level and division level. The quarterly report at division level is discussed with the responsible management and scheduled for discussion by the Business Risk Committee.

The quarterly report at Group level and supervised entity level is presented to and discussed with the individual members of the EB and a.s.r. BEC and submitted to the Audit & Risk Committee of the Supervisory Board. The report is shared and discussed with the DNB, the AFM and the (internal and) external auditor.

B.5 Internal audit function
The Audit Department provides a professional and independent assessment of the governance, risk management and internal control processes with the aim of aiding management in achieving the company’s objectives. This statement of duties has been set down in the Audit Charter for ASR Nederland N.V. and its subsidiaries. The Audit Department reports its findings to the managing board of ASR Aanvullende Ziektekostenverzekeringen N.V. and, by means of the quarterly management report, to the a.s.r. Business Executive Committee and to the Supervisory Board of ASR Aanvullende Ziektekostenverzekeringen N.V.

The Audit Department has an independent position within a.s.r., as set down in the Audit Charter. The Supervisory Board of ASR Nederland N.V. guarantees Audit and its employees an independent, impartial and autonomous position in order to execute the mission of Audit. The head of the Audit Department reports to the chairman of the Executive Board of ASR Nederland N.V. and has a reporting line to the chairman of the Supervisory Board of ASR Aanvullende Ziektekostenverzekeringen N.V. and to the chairman of the a.s.r. Audit and Risk Committee. The Chief Audit Executive is appointed by the Supervisory Board of ASR Nederland N.V. In order to maintain the independence and impartiality of the internal audit function, the audit function is not influenced by the Executive Board of ASR Nederland N.V. and the managing board of ASR Aanvullende Ziektekostenverzekeringen N.V. in the execution of an audit and the evaluation of and reporting on audit outcomes. The audit function is not subjected to any inappropriate influence from any other function, including the key functions.

The persons carrying out the internal audit function do not assume any responsibility for any other (key) function. The Audit Department has periodic consultations with the Dutch Central Bank to discuss the risk assessment, findings and audit plan. The department also takes the initiative to organize a ‘tripartite consultation’ with DNB and the independent external auditor at least once a year. In 2019, at the request of the Dutch Central Bank, no tripartite consultation was held for ASR Aanvullende Ziektekostenverzekeringen N.V.
The Audit Department sets up a multi-year audit plan based upon an extensive risk assessment. The Audit Department’s risk assessment is performed in close consultation with the independent external auditor. The audit plan is approved by the Supervisory Board of ASR Aanvullende Ziektekostenverzekeringen N.V. and the a.s.r. Audit and Risk Committee. At least once a year, the audit plan is evaluated and any changes to the plan must be approved by the a.s.r. Audit and Risk Committee.

All Audit officers took the oath for the financial sector and are subject to disciplinary proceedings. All Audit officers have committed themselves to the applicable code of conduct of a.s.r., follow the Code of Ethics of the Institute of Internal Auditors (IIA) and comply with the specific professional rules of the Netherlands Institute of Chartered Accountants (NBA) and the professional association for IT-auditors in the Netherlands (NOREA).

Audit applies the standards of the IIA, NBA and NOREA for the profession of internal auditing. Each year, Audit performs a self-assessment and an internal quality review and reports the results to the chairman of the board and to the members of the a.s.r. Audit and Risk Committee. In accordance with the standards of the IIA, an external quality review is performed every five years. During the last review in 2016, Audit was approved by the IIA and received the Institute’s quality certificate.

B.6 Actuarial function

The Actuarial Function (AF) is one of four key functions in a.s.r.’s system of governance. The main tasks and responsibilities of the AF are to:
- coordinate the calculation of technical provisions;
- ensure the appropriateness of the methodologies, underlying models and the assumptions made in the calculation of technical provisions;
- assess the sufficiency and quality of the data used in the calculation of technical provisions;
- compare best estimates against experience;
- inform the administrative, management or supervisory body of the reliability and adequacy of the calculation of technical provisions;
- express an opinion on the overall underwriting policy;
- express an opinion on the adequacy of reinsurance arrangements; and
- contribute to the effective implementation of the risk management system.

The AF is part of the second line of defense and operates independently of both the first line (responsible for determining the technical provisions, reinsurance and underwriting), as well as the other three key functions (internal audit, risk management and compliance).

The AF for both ASR Nederland N.V. and the insurance legal entities is operationally part of a.s.r. Group Risk Management. The AF is performed by persons who have profound knowledge of actuarial and financial mathematics, proportionate to the nature, scale and complexity of the risks present in a.s.r.’s businesses.

There are two function holders. One is responsible for the legal entities in the Life segment (Individual Life, Funeral and Pensions business lines) as well as for the overall Life segment of ASR Nederland N.V. The other for the entities in the Non-life segment (Property & Casualty, Disability and Health business lines) as well as for the overall Non-life segment of ASR Nederland N.V.

The AF function is represented in several risk committees. Each year, the AF drafts a formal report, which it discusses with the BEC – Risk meeting (or EB) and the a.s.r. Audit & Risk Committee.

Independence of the AF is secured through several measures:
- The AF holders are appointed and dismissed by the Board. Both the appointment and the dismissal of the holders is, together with an advice from the Audit and Risk Committee, submitted to the Supervisory Board for approval;
- The AF holders have unrestricted access to all relevant information necessary for the exercise of their function;
- The AF holders have a direct reporting line to the BEC – Risk meeting or EB and the Audit and Risk Committee of a.s.r.
- The AF is free to report to any committee when considered necessary;
- The AF is free to report all relevant issues;
- In case of a conflict of interest with the CRO, the function holders may escalate directly to the CEO and to the Chairperson of the Audit & Risk Committee of a.s.r.;
- If the AF is asked to perform tasks that are outside the formal scope described in a charter, the function holder(s) assess if there is a conflict of interest. If so, the AF will not execute the task unless there are sufficient additional measures to mitigate conflicts of interest;
• The Internal Audit Department conducts an annual assessment of the functioning of the governance of a.s.r. including the (independent) operation of the AF;
• Target Setting and assessment of the function holders is done by the CEO taking into account the opinion of the Audit & Risk Committee.

B.7 Outsourcing

a.s.r. has outsourced some of its (operational) activities and/or processes to external service providers. When activities are outsourced, a.s.r. is fully accountable for these activities and data used and a.s.r. retains full control over the outsourced activities. To manage the risks related to outsourcing, a.s.r. has implemented a policy to safeguard controlled and sound business operations which ensures compliance with laws and regulatory requirements. Solid risk management, governance, monitoring and a complete overview are essential to manage outsourced activities. The outsourcing policy outlines the relevant procedures and is applicable to a.s.r. and its subsidiaries. The policy is also applicable to intragroup outsourcing.

To define the respective rights and obligations, a.s.r. drafts a written outsourcing contract with the service provider. The contract includes amongst others the obligations for all parties involved, commitment to comply with applicable laws and regulatory requirements, right to audit and information security requirements. Confidentiality, quality of service, and continuity are key for a.s.r. in carrying out its activities. To safeguard the quality of outsourced activities, service providers are carefully examined prior to selection and during the period of service provision. a.s.r. monitors compliancy with the terms of the contract. The findings of the monitoring activities serve as input for the regular consultation on operational, tactical and strategic level with the service provider.

a.s.r. has outsourced certain critical and/or important activities that are part of material (operational) processes. Outsourced activities are related to front-, mid- or back office activities related to the supervised entities. In addition, the management and service of some supporting systems is outsourced.

B.8 Any other information

Other material information about the system of governance does not apply.
C Risk profile

This paragraph contains a description of group policy, which is applicable for the solo entity. Risk management is an integral part of a.s.r.'s day-to-day business operations. a.s.r. applies an integrated approach to managing risks, ensuring that strategic objectives are met. Value is created by striking the right balance between risk, return and capital whilst ensuring that obligations to stakeholders are met.

Risk appetite
ASR Aanvullende Ziektekostenverzekeringen N.V. is exposed to a number of risks, including strategic risks, market risks, counterparty default risks, liquidity risks, underwriting risks and operational risks.

Risk appetite is defined as the level and type of risk a.s.r. is willing to bear in order to meet its objectives while maintaining the right balance between risk, return and capital. Risk appetite is formulated to give direction to the management of (strategic) risks. Risk appetite contains a number of qualitative and quantitative risk appetite statements and is defined for both financial risks (FR) and non-financial risks (NFR). The statements highlight the organisation's risk preferences and limits and are viewed as key elements for the realisation of a.s.r.'s strategy.

In 2019, to ensure alignment with a.s.r.'s strategy, the risk appetite statements and limits were evaluated and updated by the EB and approved by the SB.

Management of financial risks
ASR Aanvullende Ziektekostenverzekeringen N.V. strives for an optimum trade-off between capital, risk and return. Steering on capital, risk and return is done by decision-making throughout the entire product cycle from PARP (Product Approval & Review Process) to the payment of benefits and claims. At a more strategic level, decision-making takes place through balance sheet management. A robust solvency position takes precedence over profit, premium income and direct investment income. Risk tolerance levels and limits are disclosed in the financial risk appetite statements (financial RAS) and are monitored by the Financial Risk Committee (FRC). The FRC evaluates financial risk positions against the RAS on a monthly basis. Where appropriate, a.s.r. takes additional mitigating measures.

In 2019, the Actuarial Function (AF) performed its regulatory tasks by assessing the adequacy of the Solvency II technical provisions, giving an opinion on reinsurance and underwriting, and contributing to the Risk Management RMF. The AF report on these topics was discussed by the Executive Board, Risk Committee and Audit & Risk Committee.

Coronavirus
In December 2019, a pneumonia outbreak was reported in China which in 2020 rapidly developed into what is now commonly referred to as the coronavirus. The virus has resulted in a significant number of confirmed cases of infection in large portions of the world, including the Netherlands. Globally, governments are taking various measures to contain the outbreak and to mitigate its impact on the economy. In the Netherlands, the Dutch government issued a series of far reaching measures to stop the spread of the coronavirus. Both the virus and the countermeasures have a significant impact on Dutch society and economics in the short term. The government has also presented a significant economic relief program to support both companies and individuals that are financially impacted by the corona outbreak. As the number of infections caused by the virus is still increasing, and the result of both the countermeasures to the virus outbreak as well as the economic relief program still has yet to take effect, the impact of the coronavirus is unsure, specifically in the longer term.

At this point in time it is too early to make a realistic and credible assessment of what the impact of the Coronavirus will be on a.s.r.'s and its subsidiaries business and financial performance. The effect on our financial results will depend on a number of factors, including the extent and duration of the period of disruption and the impact on the global economy and financial markets. However, as reported in the ASR Nederland N.V. 2019 annual report, the consolidated a.s.r. is financially healthy and its capital position is solid. The a.s.r.’s consolidated financial position at year end 2019 is strong and its Solvency II ratio of 194% based on standard model has proved resilient to absorb the extra ordinary market circumstances related to the corona outbreak so far. a.s.r. and its subsidiaries’ liquidity position of € 1.6 billion at year end 2019 has also proven resilient. We continue to closely monitor the impact of the corona outbreak on the operating performance of our various business lines. We furthermore continue to monitor the potential IFRS impact relating to the valuation of financial instruments and valuation of technical provisions which are sensitive to developments in the (long-term) interest rates.
a.s.r.’s prime concern is the personal well-being of its customers and its employees, their partners and their families. As a leading Dutch insurer, a.s.r. is committed to help its customers through this challenging period and to do everything in its power to help overcome the corona crisis in the Netherlands. To protect its employees all a.s.r. employees are working from home which most employees are already very familiar with, given the ‘independent time and place working’ policy at a.s.r.

**Management of non-financial risks**

Non-financial risk appetite statements are in place to manage the risk profile within the limits determined by the Executive Board and approved by the Supervisory Board. The Non-Financial Risk Committee (NFRC) monitors and discusses on a quarterly basis whether non-financial risks are adequately managed. Should the risk profile exceed the risk appetite, the NFRC will decide on the steps to be taken. The risk profile and internal control performance of each business is discussed with senior management in the business risk committees and the NFRC each quarter.

The most important operational risks in 2019 are described below.

Outsourcing risk (internal and external) remains relevant for a.s.r., especially in view of the increasing focus from regulators, i.e. EIOPA. a.s.r. is fully aware of the potential risks and regulatory developments. An outsourcing policy is in place defining responsibilities, processes, risk assessment and mandatory controls. Outsourcing risk is managed and reported as part of the overall operational risk. An update for the outsourcing policy is scheduled for the forthcoming year.

Information security risk is highly relevant for a.s.r. See risk priority 3 (see next page). Information (cyber) security risks for further information.

Data quality and end-user computing are also relevant for a.s.r. When user-defined models (e.g. spreadsheets) are used to support the RM Framework, the ‘a.s.r. Standard for end-user computing’ - as well as the general security policy - defines and describes best practices in order to guard the reliability and confidentiality of these tools and models. a.s.r. recognises the importance of sound data quality and information management systems.

During 2019, ASR Aanvullende Ziektekostenverzekeringen N.V. took various actions to further enhance the measurement and reporting of data quality for financial reporting purposes and to mitigate end-user computing risks. Adherence to the “a.s.r. Standard for End-User Computing” is accommodated by the explicit integration of relevant controls into the Risk and control frameworks of the business lines.

ASR Aanvullende Ziektekostenverzekeringen N.V. will continue to look for opportunities to improve the management of its non-financial risks in 2020, for example by focusing on the use of application controls and data analytics. New developments such as Artificial Intelligence (AI) and robotics and their effects on risk management will also be further explored.

In 2019, all business units applied the Governance and Risk Compliance (GRC) tool (‘Cerrix’). The functionality and performance of this tool were improved in 2019. In 2020, a.s.r. will continue to seek opportunities to improve the management of its operational risks in 2020, including the use of data analysis.

In order to enhance controlled (efficient and effective) projects, a.s.r. rolled out the ‘project risk management’ policy. Implementation of the policy is expected to be completed in 2019 for all projects. In 2019, the most important projects at a.s.r., including IFRS 9/17, Servicebooks and a.s.r. Vitality, fell within risk the appetite.

**Risk priorities**

ASR Aanvullende Ziektekostenverzekeringen N.V.’s risk priorities and emerging risks are defined annually by the Executive Board, based on strategic (top-down and bottom-up) risk analyses.

ASR Aanvullende Ziektekostenverzekeringen N.V.’s risk priorities for 2019 were:

1. Higher than market average risk of incurred losses;
2. Non-competitive premium as a result of (direct and recharged costs) organization costs; and
3. Information (cyber) security risk.

To determine the degrees of risk, ASR Aanvullende Ziektekostenverzekeringen N.V. uses a risk scale based on likelihood and impact (Level of Concern). For each risk priority, the degree of risk is determined for the gross risk and net risk. Gross risk is the degree of risk when no (control) measures are in place. Net risk is the degree of risk taking into account mitigating (control) measures. Each of ASR Aanvullende Ziektekostenverzekeringen N.V.’s risk priorities has a very high degree of gross risk (exceeds risk appetite boundaries) and a high degree of net risk (exceeds risk appetite boundaries).
ASR Aanvullende Ziektekostenverzekeringen N.V. takes measures to mitigate the net risks so that they will fall within the risk boundaries. The measures for each risk priority are described in below.

**Higher than market average risk of incurred losses**

There is a trend that risks are increasingly placed with health insurers, leading to volatility of incurred losses that cannot be accounted for in (competitive) premiums and which therefore have to be retrieved from the company’s own equity. This can result in solvability decline and other financial consequences.

**Non-competitive premium as a result of organization costs**

A smaller portfolio in an increasingly price sensitive market can prompt diseconomies of scale when spreading operational costs, resulting in a non-competitive premium.

**Information (cyber) security risk**

Information (cyber) security risks are continuously evolving and imminent. Nation state actors are (covertly) probing and intruding, pushing the development of more sophisticated attacks and implicitly the progression of new detection measures to improve ‘older’ detection techniques. The trend of cyber-attacks continues where it left off in 2018; i.e. the same type of attacks are visible around the world and at ASR Aanvullende Ziektekostenverzekeringen N.V. The growth in digital communication is also increasing the risks of cyber-attacks, as is the introduction of technological initiatives.

Increased focus on, and attention for, emerging cyber security risks is a daily requirement for ASR Aanvullende Ziektekostenverzekeringen N.V. and its supply chain. Investing in detection and prevention skills and techniques and learning from incidents in the financial industry strengthens cyber resilience. Since the battle against malicious intentions is ongoing, cyber security efforts continued to dominate risk reports in 2019.

ASR Aanvullende Ziektekostenverzekeringen N.V. is aware of the trust invested in it by its customers, and makes conscious choices in the risk exposure it is willing to tolerate. A dedicated cybersecurity team, regular testing, continuous awareness programmes and scrutinised vulnerability programmes ensure that ASR Aanvullende Ziektekostenverzekeringen N.V. is fully aware of its risks and takes measures where appropriate. All measures are continuously monitored and updated where necessary. ASR Aanvullende Ziektekostenverzekeringen N.V.’s suppliers are periodically reviewed and assessed for their cyber resilience. Partnerships with financial institutions and public agents, such as the Dutch National Cyber Security Centre (NCSC) and i-CERT (a cybersecurity partnership between insurance companies), are crucial in mounting an effective defence against cybercrime. ASR Aanvullende Ziektekostenverzekeringen N.V. is actively involved in these partnerships.

ASR Aanvullende Ziektekostenverzekeringen N.V. takes measures to mitigate risks outside the risk appetite boundaries.

**Solvency II sensitivities**

The sensitivities of the solvency ratio as at 31 December 2019, expressed as the impact on the ASR Aanvullende Ziektekostenverzekeringen N.V. solvency ratio (in percentage points) are as presented in the table below. The total impact is split between the impact on the solvency ratio related to movement in the available capital and the required capital.
Solvency II sensitivities - explanation

<table>
<thead>
<tr>
<th>Risk</th>
<th>Scenario</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest rate risk – UFR</td>
<td>Measured as the impact of a lower UFR. For the valuation of liabilities, the extrapolation to the UFR of 3.2% after the last liquid point of 20 years remained unchanged.</td>
</tr>
<tr>
<td>Interest rate risk (incl. UFR 4.05%/3.90%)</td>
<td>Measured as the impact of a parallel 1% upward and downward movement of the interest rates. For the liabilities, the extrapolation to the UFR (3.90% for 2019 and 4.05% for 2018) after the last liquid point of 20 years remained unchanged.</td>
</tr>
<tr>
<td>Volatility Adjustment</td>
<td>Measured as the impact of a 10 bps decrease in the Volatility Adjustment.</td>
</tr>
<tr>
<td>Equity risk</td>
<td>Measured as the impact of a 20% downward movement in equity prices.</td>
</tr>
<tr>
<td>Spread risk (including impact of spread movement on VA)</td>
<td>Measured as the impact of an increase of spread on loans and corporate bonds of 75 bps. At the same time, it is assumed that the Volatility Adjustment will increase by 18bps (2018 was 20 bps) based on reference portfolio.</td>
</tr>
</tbody>
</table>

The Solvency II sensitivities in 2019 are almost similar to 2018. Furthermore, the magnitude of the Solvency II sensitivities is small, as the insurances are short-cycle.

Expected development UFR
European Insurance and Occupational Pensions Authority (EIOPA) may reduce the ultimate forward rate used to extrapolate insurers’ discount curves to better reflect expected inflation and real interest rates. There are various scenarios regarding lowering the Ultimate Forward Rate (UFR).

The UFR has decreased, starting in 2018, from 4.2% in 2017 to 3.55% with steps of maximum 15 basis points per year. In 2019 the UFR was 3.9% (2018: 4.05%). After the decline of the UFR by 15 basis points the solvency ratio is still above internal solvency objectives.

Changes in the UFR have an almost linear effect on the solvency ratio. The impact on the solvency ratio of various UFR levels is stated below. Due to the short duration of the liabilities the impact of the UFR is nihil.

Sensitivity Solvency II ratio to UFR

<table>
<thead>
<tr>
<th>Percentage</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.40%</td>
<td>173</td>
<td>196</td>
</tr>
<tr>
<td>3.20%</td>
<td>173</td>
<td>196</td>
</tr>
<tr>
<td>3.90%</td>
<td>173</td>
<td>196</td>
</tr>
</tbody>
</table>

Interest rate sensitivity of Solvency II ratio
The impact of the interest rate on the Solvency II ratio, including the UFR effect, is stated below. The UFR methodology has been applied to the shocked interest rate curve.
Equity risk
In 2019 the equity risk decreased due to a smaller equity portfolio as a result of transactions. Apart from that the equity risk decreased because of the diminishing effect of the transitional measure due to (i) higher risk charges and (ii) less equities qualifying for the transitional measure.

Spread risk
In 2019 ASR Aanvullende Ziektekostenverzekeringen N.V. the required capital for spread risk slightly decreased.

In case of a scenario in which the average spread rises by 75 bps and the Volatility Adjustment (VA) rises by 18 bps, the solvency ratio decreases -2%. As the impact of the rise in VA on the calculation of the liabilities is limited due to the short duration, the impact of the spread rise is dominant. Therefore, the solvency ratio decreases in the event of an increase in the average spread.

Loss absorbing capacity of deferred tax
a.s.r. uses the following methodology for the calculation of the Loss Absorbing Capacity Deferred Tax (LAC DT) benefit in euros of ASR Aanvullende Ziektekostenverzekeringen N.V.

Relevant regulation and current guidance (Delegated Regulation, Level 3 guidelines, Dutch Central Bank Q&As and IAS12) are taken into account in the development of the LAC DT methodology.

<table>
<thead>
<tr>
<th>LAC DT Components</th>
<th>ASR Aanvullende Ziektekostenverzekeringen N.V.</th>
<th>Available for substantiation</th>
<th>Utilised in applied LAC DT factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model sort</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Component 1 – Taxable profit (t)</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Component 2 – Taxable profit (t-1)</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Component 3 – Net DTL position</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Component 4a – Risk Margin</td>
<td>✓</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Component 4b – Future taxable profit</td>
<td>✓</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>
The outcome is an unrounded LAC DT factor.

1. The unrounded LAC DT factor is determined based on component 1 – 3 only.
2. Moreover, an outlook is made of the underpinning of the LAC DT factor in the upcoming quarters, divided over the separate components. This outlook will take into account potential risks not yet included in the model, also called a code of conduct. This code of conduct ensures financial stability in the LAC DT benefit ASR Aanvullende Ziektekostenverzekeringen N.V. in euros, resulting in financial stability of the solvency position of ASR Aanvullende Ziektekostenverzekeringen N.V.
3. The LAC DT factors and outlook are reviewed by the 2nd line.
4. A proposal with the advised LAC DT factors will be presented to the Financial Risk Committee (FRC). The LAC DT factors agreed with the FRC are to be applied.

A source of stability can be found in the way the LAC DT factor is adjusted if a change is desired. In case the substantiation of the LAC DT is too low the factor is lowered immediately, taking into account the code of conduct. However, in case an increase is possible, it is only realized in case it is sustainable and significant.

### C.1 Insurance risk

Insurance risk is the risk that future insurance claims and benefits cannot be covered by premium and/or investment income, or that insurance liabilities are not sufficient, because future expenses, claims and benefits differ from the assumptions used in determining the best estimate liability. The healthcare sector is part of the non-life portfolio.

The solvency buffer is held by ASR Aanvullende Ziektekostenverzekeringen N.V. to cover the risk that claims may exceed the available insurance provisions and to ensure its solidity. The solvency position of ASR Aanvullende Ziektekostenverzekeringen N.V. is determined and continuously monitored in order to assess if ASR Aanvullende Ziektekostenverzekeringen N.V. meets the regulatory requirements.

As of 1 January 2016, the Solvency II regime is in place. ASR Aanvullende Ziektekostenverzekeringen N.V. measures its risks based on the standard model as prescribed by the Solvency II regime. The Solvency Capital Requirement for each insurance risk is determined as the change in own funds caused by a predetermined shock which is calibrated to a 1-in-200-year event. The basis for these calculations are the Solvency II technical provisions which are calculated as the sum of a best estimate and a risk margin.

The insurance risk arising from the health insurance portfolio of ASR Aanvullende Ziektekostenverzekeringen N.V. is as follows.

<table>
<thead>
<tr>
<th>Insurance risk - required capital</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health insurance risk</td>
<td>12,221</td>
<td>11,503</td>
</tr>
</tbody>
</table>

### C.1.1 Health insurance risk

The Health insurance portfolio of ASR Aanvullende Ziektekostenverzekeringen N.V. contains the following insurance risk:
- **NSLT Health insurance risk**
  - This risk is applicable to the NSLT Health portfolio. The calculation is factor-based. The risk is calculated similar to the Non-Life insurance risk Solvency II standard model.

#### NSLT Health Risk

**Premium and reserve risk**

The premium risk is the risk that the premium is not adequate for the underwritten risk. The premium risk is calculated over the maximum of the expected earned premium of the next year, and the earned premium of the current year.

Reserve risk is the risk that the current reserves are insufficient to cover the claims over a 12-month time horizon.

There is an increase in the Health insurance risk at the end of 2019 because the amount of insurance contracts for the portfolio 2020 has increased as of 2019Q4.
### Insurance risk - required capital

<table>
<thead>
<tr>
<th>in € thousand</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health SLT</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Health Non-SLT</td>
<td>12,221</td>
<td>11,503</td>
</tr>
<tr>
<td>Catastrophe Risk (subtotal)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Health (Total)</strong></td>
<td>12,221</td>
<td>11,503</td>
</tr>
<tr>
<td>Medical expenses insurance and proportional reinsurance</td>
<td>12,221</td>
<td>11,503</td>
</tr>
<tr>
<td>Income protection insurance and proportional reinsurance</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Health SLT (subtotal)</strong></td>
<td>12,221</td>
<td>11,503</td>
</tr>
<tr>
<td>Mass accident risk</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Accident concentration risk</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pandemic risk</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Catastrophe risk (subtotal)</strong></td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

For the NSLT Health portfolio, the technical provision at year-end can be broken down as follows under Solvency II:

### Insurance with profit participation

<table>
<thead>
<tr>
<th>in € thousand</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best estimate</td>
<td>-2,998</td>
<td>1,288</td>
</tr>
<tr>
<td>Risk margin</td>
<td>937</td>
<td>891</td>
</tr>
<tr>
<td><strong>Technical provision</strong></td>
<td>-2,061</td>
<td>2,179</td>
</tr>
</tbody>
</table>

### C.1.2 Managing health insurance risk

Health insurance risk is managed by monitoring claims frequency, the size of claims, inflation, handling time, benefit and claims handling costs. Concentration risk also qualifies as an insurance risk.

#### Claims frequency, size of claim and inflation

To mitigate the risk of claims, ASR Aanvullende Ziektekostenverzekeringen N.V. bases its underwriting policy on claims history and risk models. The policy is applied to each client segment and to each type of activity. In order to limit claims and/or ensure that prices are adjusted correctly, the product line health NSLT also uses knowledge or expectations with respect to future trends to estimate the frequency, size and inflation of claims. The risk of unexpected major damage claims is contained by policy limits.

#### Handling time

The handling time for health care claims is generally very short and the settlement occurs quickly. Normally, within one to five days a claim is settled.

#### Benefit and claims handling costs

Taking estimated future inflation into account, benefit and claims handling costs are managed based on regular reviews and related actions.

#### Concentration risk

Geographically, the risk exposure of ASR Aanvullende Ziektekostenverzekeringen N.V. on its health portfolio is almost entirely concentrated in the Netherlands.
C.2 Market risk

Market risk is the risk of potential losses due to adverse movements in financial market variables. Exposure to market risk is measured by the impact of movements in financial variables such as equity prices, interest rates and property prices. The various types of market risk which are discussed in this section, are:

- interest rate risk
- equity risk
- property risk
- currency risk
- spread risk
- concentration risk

Market risk reports are submitted to the FRC at least once a month. Key reports on market risk include the Solvency II and economic capital report, the interest rate risk report and the report on risk budgets related to the strategic asset mix.

A summary of sensitivities to market risks for the regulatory solvency, total equity and profit for the year is presented in the tables below. The first table summarizes the required capital for market risks based on the standard model:

<table>
<thead>
<tr>
<th>Market risk - required capital</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest rate</td>
<td>450</td>
<td>481</td>
</tr>
<tr>
<td>Equity</td>
<td>840</td>
<td>1,065</td>
</tr>
<tr>
<td>Property</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Currency</td>
<td>-</td>
<td>7</td>
</tr>
<tr>
<td>Spread</td>
<td>888</td>
<td>798</td>
</tr>
<tr>
<td>Concentration</td>
<td>109</td>
<td>75</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-606</td>
<td>-429</td>
</tr>
<tr>
<td>Total</td>
<td>1,681</td>
<td>1,814</td>
</tr>
</tbody>
</table>

The main market risks of ASR Aanvullende Ziektekostenverzekeringen N.V. are spread and equity risk. This is in line with the risk budgets based on the strategic asset allocation study.

The interest rate risk is the maximum loss of (i) an upward shock or (ii) a downward shock of the yield curve. ASR Aanvullende Ziektekostenverzekeringen N.V. the upward shock is dominant.

ASR Aanvullende Ziektekostenverzekeringen N.V. applies the transitional measure for equity risk for shares in portfolio at 31 December 2015. The SCR equity shock was 22% at 31 December 2015 and linear, increasing to (i) 39% + equity dampener for type I shares and (ii) 49% + equity dampener for type II shares. The equity dampener has a value between -10% and 10%. In the event of increasing equity prices, the equity dampener will have a smaller dampening effect.

C.2.1 Interest rate risk

Interest rate risk is the risk that the value of assets, liabilities or financial instruments will change due to fluctuations in interest rates. Many insurance products are exposed to interest rate risk; the value of the products is closely related to the applicable interest rate curve. The interest rate risk of insurance products depends on the term to maturity, interest rate guarantees and profit-sharing features. Life insurance contracts are particularly sensitive to interest rate risk. The required capital for interest rate risk is determined by calculating the impact on the available capital due to changes in the yield curve. Both assets and liabilities are taken into account. The interest rate risk is the maximum loss of (i) an upward shock or (ii) a downward shock of the yield curve according to the prescribed methodology. a.s.r. applies a look-through approach for investment funds to assess the interest rate risk.

The interest rate risk is calculated by a relative shock up- and downward shock of the risk-free (basis) yield curve. All adjustments (credit spread, volatility adjustment) on this yield curve are considered constant. The yield curve is extrapolated to the UFR. The yield curve after shock is not extrapolated again to the UFR.
The used shocks vary by maturity and the absolute shocks are higher for shorter maturities (descending: 75% to 20% and ascending: -70% to -20%):
- the yield curve up shock contains a minimum shock of 100bps;
- the yield curve after the downward shock is limited to zero (no negative interest rates);
- the yield curves of all currencies are shocked simultaneously.

### Interest rate risk - required capital

<table>
<thead>
<tr>
<th></th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCR interest rate risk up</td>
<td>-450</td>
<td>-481</td>
</tr>
<tr>
<td>SCR interest rate risk down</td>
<td>23</td>
<td>43</td>
</tr>
<tr>
<td>SCR interest rate risk</td>
<td>450</td>
<td>481</td>
</tr>
</tbody>
</table>

ASR Aanvullende Ziektekostenverzekeringen N.V. has assessed various scenarios to determine the sensitivity to interest rate risk. The impact on the solvency ratio is calculated by determining the difference in the change in available and required capital.

### Solvency II sensitivities - interest rate

<table>
<thead>
<tr>
<th>Effect on:</th>
<th>Available capital</th>
<th>Required capital</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scenario (%-point)</td>
<td>31 December 2019</td>
<td>31 December 2018</td>
<td>31 December 2019</td>
</tr>
<tr>
<td>UFR 3.2%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Interest rate +1% (2018 incl. UFR 4.05% / 2019 incl. UFR 3.90%)</td>
<td>-2</td>
<td>-2</td>
<td>-</td>
</tr>
<tr>
<td>Interest rate -1% (2018 incl. UFR 4.05% / 2019 incl. UFR 3.90%)</td>
<td>+2</td>
<td>+2</td>
<td>-</td>
</tr>
<tr>
<td>Volatility Adjustment -10bp</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Interest rate risk is managed by aligning fixed-income investments to the profile of the liabilities. Among other instruments, swaptions and interest rate swaps are used for hedging the specific interest rate risk arising from interest rate guarantees and profit sharing features in life insurance products.

### C.2.2 Equity risk

The equity risk depends on the total exposure to equities. In order to maintain a good understanding of the actual equity risk, a.s.r. applies the look-through approach for investment funds to assess the equity risk.

The required capital for equity risk is determined by calculating the impact on the available capital due to an immediate drop in share prices. Both assets and liabilities are taken into account. Stocks listed in regulated markets in countries in the EEA or OECD are shocked by 39% together with the symmetric adjustment of the equity capital charge (type I). Stocks in countries that are not members of the EEA or OECD, unlisted equities, alternative investments, or investment funds in which the look-through principle is not possible, are shocked by 49% together with the symmetric adjustment of the equity capital charge (type II).

ASR Aanvullende Ziektekostenverzekeringen N.V. applies the transitional measure for equity risk for shares in portfolio at 31 December 2015. The SCR equity shock was 22% at 31 December 2015 and linear increasing in 7 years to (i) 39% + equity dampener for type I shares and (ii) 49% + equity dampener for type II shares. This resulted in a reduction of the average risk charge of equity risk of about 5,0% per 31 December 2019.

### Equity risk - required capital

<table>
<thead>
<tr>
<th></th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCR equity risk - required capital</td>
<td>840</td>
<td>1,065</td>
</tr>
</tbody>
</table>

In 2019 the equity portfolio decreased as an effect of (i) positive market returns and (ii) de-risking by selling part of the equity portfolio. In total the SCR equity risk decreased due to this smaller equity portfolio. However, there was also an upward effect due to a higher SCR charge. On the one hand this is a result of the equity dampener and on the other hand due to the run-off of the transitional measure of equity risk.
In case the transitional measure would not be used, SCR equity risk would increase to € 964 thousand.

### Solvency II sensitivities - equity prices

<table>
<thead>
<tr>
<th>Scenario (%-point)</th>
<th>Available capital</th>
<th>Required capital</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equity prices -20%</td>
<td>-3</td>
<td>+1</td>
<td>-2</td>
</tr>
</tbody>
</table>

**Composition of equity portfolio**

The fair value of equities and similar investments at year-end 2019 was € 2,477 thousand (2018: € 3,663 thousand). The decrease in 2019 was an effect of (i) positive market returns and (ii) de-risking by selling a part of the equity portfolio.

### Composition of Equity portfolio

#### Mature Markets (euro)

- 86%

#### Dutch Participations

- 14%

#### C.2.3 Property risk

Property risk is not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

#### C.2.4 Currency risk

Currency risk measures the impact of losses related to changes in currency exchange rates. The table below provides an overview of the currencies with the largest exposures. The policy of a.s.r. is in principle to hedge the currency risk excluding investments in equities and investments that are externally managed. However, certain currency exposures are permitted from a tactical perspective within a specific risk budget.

The required capital for currency risk is determined by calculating the impact on the available capital due to a change in exchange rates. Both assets and liabilities are taken into account and a look-through approach is applied for investment funds. For each currency the maximum loss due to an upward and a downward shock of 25% is determined except for a small number of currencies where lower shocks are applied (Danish crown; Bulgarian lev).

### Currency risk - required capital

<table>
<thead>
<tr>
<th>SCR currency risk - required capital</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-7</td>
<td>7</td>
</tr>
</tbody>
</table>

Currency risk has decreased 7 thousand, due to the decrease in foreign bonds. The currency risk as per 31 December 2019 equals just below 0,5 thousand.
Specification currencies with largest exposure
Foreign bonds have substantially decreased in the following currencies: USD.

Composition currency portfolio

C.2.5 Spread risk
Spread risk arises from the sensitivity of the value of assets and liabilities to changes in the level of credit spreads on the relevant risk-free interest rates. a.s.r. has a policy of maintaining a well-diversified high-quality investment grade portfolio while avoiding large risk concentrations. Going forward, the volatility in spreads will continue to have possible short-term effects on the market value of the fixed income portfolio. In the long run, the credit spreads are expected to be realized and to contribute to the growth of the own funds. The required capital for spread risk is determined by calculating the impact on the available capital due to the volatility of credit spreads over the term structure of the risk-free rate.

The required capital for spread risk is equal to the sum of the capital requirements for bonds, structured products and credit derivatives. The capital requirement depends on (i) the market value, (ii) the modified duration and (iii) the credit quality category.

Spread risk - required capital

<table>
<thead>
<tr>
<th>SCR spread risk - required capital</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>888</td>
<td>798</td>
</tr>
</tbody>
</table>

The SCR spread risk increased in 2019, mainly due to a larger fixed income portfolio, the decrease in interest rates also contributed to increase of the SCR spread. On the other hand SCR spread risk decreased due to the shortening duration of the credit portfolio.

The sensitivity to spread risk is measured as the impact of an increase of spread on loans and corporate bonds of 75 bps. The volatility adjustment is based on a reference portfolio. An increase of 75 bps of the spreads on loans and corporate bonds within the reference portfolio leads to an increase of the VA with 18 bps in 2019 (2018: 20 bps).

Solvency II sensitivities - spread risk

<table>
<thead>
<tr>
<th>Effect on:</th>
<th>Available capital</th>
<th>Required capital</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spread +75bps/(2018: VA +20bps/2019: VA + 18bps)</td>
<td>-2</td>
<td>-2</td>
<td>-2</td>
</tr>
</tbody>
</table>

Composition of fixed income portfolio
Spread risk is managed on a portfolio basis within limits and risk budgets established by the relevant risk committees. Where relevant, credit ratings provided by the external rating agencies are used to determine risk budgets and monitor limits. A limited number of fixed-income investments do not have an external rating. These investments are generally assigned an internal rating. Internal ratings are based on methodologies and rating classifications similar to those used by external agencies. The following tables provide a detailed breakdown of the fixed-income exposure by (i) rating class and (ii) sector. Assets in scope of spread risk are, by definition, not in scope of counterparty default risk.
The total exposure of assets in scope of spread risk is € 27,116 thousand (2018: € 35,920 thousand). The decrease of the portfolio is mainly due a dividend upstream. These transactions leads to changes in the portfolio decomposition:
- the relatively amount of government core decreased and the relatively amount of other categories increased;
- the relatively amount of AAA rated bonds decreased and the relatively amount of A and BBB rated bonds increased.

Composition of fixed income by sector portfolio

<table>
<thead>
<tr>
<th>Sector</th>
<th>Composition 2019</th>
<th>Composition 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government core</td>
<td>13%</td>
<td>23%</td>
</tr>
<tr>
<td>Government non core</td>
<td>41%</td>
<td>37%</td>
</tr>
<tr>
<td>Financials</td>
<td>37%</td>
<td>21%</td>
</tr>
<tr>
<td>Corporates</td>
<td>14%</td>
<td>23%</td>
</tr>
</tbody>
</table>

Composition of fixed income portfolio by rating

<table>
<thead>
<tr>
<th>Rating</th>
<th>Composition 2019</th>
<th>Composition 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>23%</td>
<td>23%</td>
</tr>
<tr>
<td>AA</td>
<td>17%</td>
<td>39%</td>
</tr>
<tr>
<td>A</td>
<td>33%</td>
<td>22%</td>
</tr>
<tr>
<td>BBB</td>
<td>22%</td>
<td>17%</td>
</tr>
<tr>
<td>Lower than BBB</td>
<td>22%</td>
<td>Not rated</td>
</tr>
<tr>
<td>Not rated</td>
<td>33%</td>
<td>23%</td>
</tr>
</tbody>
</table>

C.2.6 Market risk concentrations

Concentrations of market risk constitute an additional risk to an insurer. Concentration risk is the concentration of exposures to the same counterparty. Other possible concentrations (region, country, etc.) are not in scope. The capital requirement for concentration risk is determined in three steps:
1. determine the exposure above threshold. The threshold depends on the credit quality of the counterparty;
2. calculation of the capital requirement for each counterparty, based on a specified factor depending on the credit quality;
3. aggregation of individual capital requirements for the various counterparties.

According the spread risk module, bonds and loans guaranteed by a certain government or international organisation are not in scope of concentration risk. Bank deposits can be excluded from concentration risk if they fulfil certain conditions.

<table>
<thead>
<tr>
<th>Concentration risk - required capital</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCR concentration risk - required capital</td>
<td>109</td>
<td>75</td>
</tr>
</tbody>
</table>

In order to avoid concentrations in a single obligor, a.s.r. applies a limit on maximum exposure for (i) issuers with a single A rating and higher and (ii) for issuers with a BBB rating on group level. The limits apply to the total investment portfolio, where government bonds are not included, which is consistent with Solvency II. Beside the limits on single obligors, a.s.r. applies also limits on the total level of the required capital for market risk concentrations for ASR Aanvullende Ziektekosten N.V. Due to a well-diversified investment portfolio, no material market risk concentrations occurs.
C.3 Counterparty default risk

Counterparty default risk reflects possible losses due to unexpected default or deterioration in the credit standing of counterparties and debtors. Counterparty default risk affects several types of assets:

- mortgages
- savings-linked mortgage loans ("Spaarlossen")
- derivatives
- reinsurance
- receivables
- cash and deposits

Assets that are in scope of spread risk are, by definition, not in scope of counterparty default risk and vice versa. The Solvency II regime makes a distinction between two types of exposures:

- Type 1: These counterparties generally have a rating (reinsurance, derivatives, current account balances, deposits with ceding companies and issued guarantee (letter of credit). The exposures are not diversified.
- Type 2: These counterparties are normally unrated (receivables from intermediaries and policyholders, mortgages with private individuals or SMEs). The exposures are generally diversified.

The total capital requirement for counterparty risk is an aggregation of the capital requirement for type 1 exposure and the capital requirement for type 2 exposure by taking 75% correlation.

### Counterparty default risk - required capital

<table>
<thead>
<tr>
<th></th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 1</td>
<td>333</td>
<td>125</td>
</tr>
<tr>
<td>Type 2</td>
<td>82</td>
<td>91</td>
</tr>
<tr>
<td>Diversification (negative)</td>
<td>-17</td>
<td>-14</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>399</strong></td>
<td><strong>202</strong></td>
</tr>
</tbody>
</table>

The increase of Type 1 risk is the result of the increase of cash position.

C.3.1 Mortgages

ASR Aanvullende Ziektekostenverzekeringen N.V. has no mortgages on the balance sheet.

C.3.2 Savings-linked mortgage loans

ASR Aanvullende Ziektekostenverzekeringen N.V. has no saving loans on the balance sheet.

C.3.3 Derivatives

ASR Aanvullende Ziektekostenverzekeringen N.V. has no material derivatives on the balance sheet.

C.3.4 Reinsurance

ASR Aanvullende Ziektekostenverzekeringen N.V. has no reinsurance contracts on the balance sheet.

C.3.5 Receivables

### Composition receivables

<table>
<thead>
<tr>
<th></th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policyholders</td>
<td>993</td>
<td>1,169</td>
</tr>
<tr>
<td>Intermediaries</td>
<td>60</td>
<td>153</td>
</tr>
<tr>
<td>Reinsurance operations</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Health insurance fund</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td>-539</td>
<td>-564</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>513</strong></td>
<td><strong>758</strong></td>
</tr>
</tbody>
</table>
C.3.6 Cash and cash equivalents


<table>
<thead>
<tr>
<th>Composition cash accounts by rating</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AA</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>A</td>
<td>5,011</td>
<td>2,158</td>
</tr>
<tr>
<td>Lower than A</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>5,011</td>
<td>2,158</td>
</tr>
</tbody>
</table>

C.4 Liquidity risk

Liquidity risk is the risk that ASR Aanvullende Ziektekostenverzekeringen N.V. is not able to meet its financial obligations to policyholders and other creditors when they become due and payable, at a reasonable cost and in a timely manner. Liquidity risk is not quantified in the Solvency Capital Requirement of ASR Aanvullende Ziektekostenverzekeringen N.V., and is therefore separately discussed here.

ASR Aanvullende Ziektekostenverzekeringen N.V. recognises different levels of liquidity management. Short-term liquidity, or daily cash management, covers the day-to-day cash requirements under normal business conditions and targets funding liquidity risk. Long-term liquidity management considers business conditions in which market liquidity risk materialises. Stress liquidity management looks at it related to the ability to respond to a potential crisis situation as a result of a market event and an ASR Aanvullende Ziektekostenverzekeringen N.V.-specific event. Unexpected cash outflows could for example occur as result of lapses in the insurance portfolio, savings withdrawals catastrophe risk or cash variation margin payments related to the ISDA/CSA agreements of derivatives. ASR Aanvullende Ziektekostenverzekeringen N.V. monitors its liquidity risk scenarios via different risk reporting and monitoring processes including daily cash management reports, cash flow forecasts and stress scenario liquidity reports.

ASR Aanvullende Ziektekostenverzekeringen N.V.’s liquidity management principle consists of three components. First, a well-diversified funding base which is necessary in order to provide liquidity for cash management purposes. A portion of assets must be invested in unencumbered marketable securities that can be used for collateralised borrowing or asset sales. Second, the strategic asset allocation should reflect the expected and contingent liquidity needs of liabilities. Finally, an adequate and up-to-date liquidity policy and contingency liquidity plan are in place to enable management to act effectively and efficiently in times of crisis.

In managing the liquidity risk from financial liabilities, ASR Aanvullende Ziektekostenverzekeringen N.V. holds liquid assets comprising cash and cash equivalents and investment grade securities for which there is an active and liquid market. These assets can be readily sold to meet liquidity requirements. As at 31 December 2019, ASR Aanvullende Ziektekostenverzekeringen N.V. had cash (€ 4,946 thousand), liquid government bonds (€ 10,146 thousand) and other bonds and shares. Furthermore ASR Aanvullende Ziektekostenverzekeringen N.V. has access to multiple committed cash facilities and an unsecured revolving credit facility in order to meet its liquidity needs in times of stress.

The following table shows the contractual cash flows of liabilities (excluding insurance contracts on behalf of policyholders) broken down in four categories. For liabilities arising from insurance contracts, expected lapses and mortality risk are taken into account. Profit-sharing cash flow of insurance contracts is not taken into account, nor are equities, property and swaptions.
### Contractual cashflows

<table>
<thead>
<tr>
<th></th>
<th>Payable on</th>
<th>&lt; 1 years</th>
<th>1-5 years</th>
<th>5-10 years</th>
<th>&gt; 10 years</th>
<th>Undiscounted cash flows</th>
<th>Carrying value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>31 December 2019</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial Liabilities</td>
<td>-</td>
<td>-8,873</td>
<td>5,863</td>
<td>-1</td>
<td>-</td>
<td>-3,012</td>
<td>5,549</td>
</tr>
<tr>
<td>Derivatives</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance Liabilities</td>
<td>-</td>
<td>3,753</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,753</td>
<td>3,753</td>
</tr>
<tr>
<td>Future interest payments</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>-</td>
<td>-5,121</td>
<td>5,863</td>
<td>-1</td>
<td>-</td>
<td>741</td>
<td>9,301</td>
</tr>
</tbody>
</table>

|                          |                     |           |           |            |            |                         |                |
| **31 December 2018**     |                     |           |           |            |            |                         |                |
| Financial Liabilities    | -                   | -4,348    | 5,636     | -          | -          | 1,288                   | 5,451          |
| Derivatives              | -                   | -         | -         | -          | -          | 5                       |                |
| Insurance Liabilities    | 416                 | 6,206     | -         | -          | 4,992      | 11,613                  | 11,613         |
| Future interest payments | -                   | 200       | 799       | 998        | 4,176      | 6,173                   |                |
| **Total**                | 416                 | 2,058     | 6,435     | 998        | 9,168      | 19,075                  | 17,070         |

When the amount payable is not fixed the amount reported is determined by reference to the conditions existing at the reporting date.

Financial liabilities payable on demand include the liability recognised for cash collateral received under ISDAs, concluded with counterparties. The related cash collateral received is recognised as cash and cash equivalents, and not part of the liquidity risk exposure table.

**EPIFP**

With regard to liquidity risk, ‘the expected profit included in future premiums’ (“EPIFP”) means the expected present value of future cash flows which result from the inclusion in technical provisions of premiums relating to existing insurance and reinsurance contracts that are expected to be received in the future, but that may not be received for any reason, other than because the insured event has occurred, regardless of the legal or contractual rights of the policyholder to discontinue the policy.

### EPIFP

<table>
<thead>
<tr>
<th></th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPIFP</td>
<td>7,566</td>
<td>3,477</td>
</tr>
</tbody>
</table>

**C.5 Operational risk**

Operational risk is the risk of losses resulting from inadequate or failing internal processes, persons and systems, or from external events (including legal risk). The main areas where operational risks are incurred are operations, IT, outsourcing, integrity and legal issues.

### Operational risk - required capital

<table>
<thead>
<tr>
<th></th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCR operational risk - required capital</td>
<td>2,163</td>
<td>2,175</td>
</tr>
</tbody>
</table>

The SCR for operational risk amounts to € 2,163 thousand at the end of 2019 and is determined with the standard formula under Solvency II. The operational risk is based on the basic solvency capital requirement, the volumes of premiums and technical provisions, and the amount of expenses.
C.6 Other material risks

As part of the regular ORSA process, the overall risk profile and associated solvency capital needs are assessed against a.s.r.’s actual solvency capital position. The most important risks to which a.s.r. is exposed, including risks that are not incorporated into the standard formula, are identified through a combined top-down (strategic risk assessment) and bottom-up (control risk self-assessments) approach. After assessment of the effectiveness of the mitigating measures, the risks with the highest ‘Level of Concern’ or ‘LoC’ are translated to the a.s.r. risk priorities and relevant risk scenarios for the ORSA. The following risks, outside the scope of the standard formula, are recognised by a.s.r. as being potentially material:

- Inflation risk;
- Reputation risk;
- Liquidity risk;
- Contagion risk;
- Legal environment risk;
- Model risk;
- Risks arising from non-insurance activities (non-OTSOs);
- Strategic risk;
- Emerging risk.

As part of the appropriateness assessment of the standard formula mitigating measures regarding these risks are identified and evaluated.

C.7 Any other information

C.7.1 Description of off-balance sheet positions
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

C.7.2 Reinsurance policy and risk budgeting

C.7.2.1 Reinsurance policy
ASR Aanvullende Ziektekostenverzekeringen N.V. does not reinsure any specific underwriting risk at this moment.

C.7.2.2 Risk budgeting
The FRC assesses the solvency position and the financial risk profile on a monthly basis. Action is taken where appropriate to ensure the predefined levels in the risk appetite statement will not be violated.

C.7.3 Monitoring of new and existing products
Group Risk Management, Compliance, and Legal Affairs participate in the product approval committee (PARP). All these departments evaluate whether risks in newly developed products are sufficiently addressed. New products need to be developed in a way that they are cost efficient, reliable, useful and secure. New products must also be strategically aligned with a.s.r.’s mission to be a solid and trustworthy insurer. In addition, the risks of existing products are evaluated, as requested by the PARP, as a result of product reviews.

C.7.4 Prudent person principle
a.s.r. complies with the prudent person principles as set out in Directive 2009/138/EC/article 132: Prudent person principle. The prudent person principle ensures that assets are managed on behalf of its subsidiaries, policyholders or other stakeholders in a prudent manner, and covers aspects that relate to market, credit, liquidity and operational risk. a.s.r. has mandated ASR Vermogensbeheer N.V. as their asset manager.

a.s.r. ensures that assets of policyholders or other stakeholders are managed in a prudent manner. a.s.r. complies with the “Prudent Person Principle” by investing only in assets and instruments which a.s.r. can adequately assess, measure, monitor, control, maintain and report the risks. All assets will be assessed against solvency criteria according to article 45 (1a).

Derivatives are only used when these contribute to a lower risk or when it can be used to manage/hedge the portfolio more efficient. Mortgages, real estate and illiquid assets, which are not traded on regulated financial markets, are limited to a prudent level.
Governance of Investments

Within the Three Lines-of-Defence model, investments are managed in the first line by ASR Vermogensbeheer N.V., reporting to the CFO of a.s.r.

ASR Vermogensbeheer N.V. manages its investments within the boundaries of a.s.r.’s Risk Appetite Framework, Strategic Asset Allocation and its Market-Risk Budget. The Market-Risk Budget is calculated on a monthly basis by Group Balance Sheet Management (GBSM), taking into account the Risk Appetite Framework. Group Risk Management, acting as the second line of defence, is responsible for the review. Internal Audit acts as the third-line of defence.

a.s.r. has established a structure of risk committees with the objective to monitor the risk profile for a.s.r. group, its legal entities and its business lines in order to ensure that it remains within the risk appetite and the underlying risk tolerances and risk limits. When triggers are hit or likely to be hit, risk committees make decisions regarding measures to be taken, being risk-mitigating measures or measures regarding governance, such as the frequency of their meetings.

All investment related activities are performed according to mandates as set by a.s.r., clients or policyholders. Mandates for investments for own account, clients and for account of policyholders are set out in internal guidelines, in order to ensure that prudent person principles are satisfied. This should always be in line with internal policies and internal constraints (such as a.s.r.’s ESG policy) and external constraints (such as regulatory limits).
This chapter contains information regarding the valuation of the balance sheet items. For each material asset class, the bases, methods and main assumptions used for valuation for solvency purposes are described. Separately for each material class of assets a quantitative and qualitative explanation of any material difference between the valuation for solvency purposes and valuation in the financial statements. When accounting principles are equal or when line items are not material, some line items are clustered together.

Valuation of assets is based on fair value measurement as described below. Each material asset class is described in paragraph D.1. Valuation of technical provisions is calculated as the sum of the best estimate and the risk margin. This is described in paragraph D.2. Other liabilities are described in paragraph D.3.

Information for each material line item is based on the balance sheet below. For each line item is described:

- Methods and assumptions for valuation
- Difference between solvency valuation and valuation in the financial statements

The numbering of the line items refers to the comments below.

Based on the differences in this template a reconciliation is made between IFRS equity and Solvency equity for 2019.

### Reconciliation IFRS balance sheet and Solvency II balance sheet

<table>
<thead>
<tr>
<th>Balance sheet</th>
<th>31 December 2019 IFRS</th>
<th>Revaluation</th>
<th>31 December 2019 Solvency II</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Deferred acquisition costs</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2. Intangible assets</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3. Deferred tax assets</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4. Property, plant, and equipment held for own use</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5. Investments - Property (other than for own use)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6. Investments - Equity</td>
<td>2,477</td>
<td>-</td>
<td>2,477</td>
</tr>
<tr>
<td>7. Investments - Bonds</td>
<td>27,116</td>
<td>-</td>
<td>27,116</td>
</tr>
<tr>
<td>8. Investments - Derivatives</td>
<td>8</td>
<td>-</td>
<td>8</td>
</tr>
<tr>
<td>9. Unit-linked investments</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10. Loans and mortgages</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11. Reinsurance</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>12. Cash and cash equivalents</td>
<td>4,946</td>
<td>-</td>
<td>4,946</td>
</tr>
<tr>
<td>13. Any other assets, not elsewhere shown</td>
<td>1,137</td>
<td>-</td>
<td>1,137</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>5,549</td>
<td>-8,547</td>
<td>-2,998</td>
</tr>
<tr>
<td>14. Technical provisions (best estimates)</td>
<td>-</td>
<td>937</td>
<td>937</td>
</tr>
<tr>
<td>15. Technical provisions (risk margin)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>16. Unit-linked best estimate</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>17. Unit-linked risk margin</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>18. Pension benefit obligations</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>19. Deferred tax liabilities</td>
<td>186</td>
<td>1,902</td>
<td>2,089</td>
</tr>
<tr>
<td>20. Subordinated liabilities</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>16,967</td>
<td>-5,707</td>
<td>11,260</td>
</tr>
<tr>
<td><strong>Excess of assets over liabilities</strong></td>
<td>18,717</td>
<td>5,707</td>
<td>24,424</td>
</tr>
</tbody>
</table>
This chapter contains also the reconciliation between the excess of assets over liabilities to EOF.

### Reconciliation excess of assets over liabilities to Eligible Own Funds

<table>
<thead>
<tr>
<th></th>
<th>Gross of tax 31 December 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IFRS equity</strong></td>
<td>18,717</td>
</tr>
<tr>
<td><strong>Revaluation assets</strong></td>
<td></td>
</tr>
<tr>
<td>i. Intangible assets</td>
<td>-</td>
</tr>
<tr>
<td>ii. Loans and mortgages</td>
<td>-</td>
</tr>
<tr>
<td>iii. Reinsurance</td>
<td>-</td>
</tr>
<tr>
<td>iv. Cash and cash equivalents</td>
<td>-</td>
</tr>
<tr>
<td>v. Any other assets, not elsewhere shown</td>
<td>-</td>
</tr>
<tr>
<td><strong>Revaluation liabilities</strong></td>
<td></td>
</tr>
<tr>
<td>i. Technical provisions (best estimates)</td>
<td>8,547</td>
</tr>
<tr>
<td>ii. Technical provisions (risk margin)</td>
<td>-937</td>
</tr>
<tr>
<td>iii. Unit-linked best estimate</td>
<td>-</td>
</tr>
<tr>
<td>iv. Unit-linked risk margin</td>
<td>-</td>
</tr>
<tr>
<td>v. Subordinated liabilities</td>
<td>-</td>
</tr>
<tr>
<td>vi. Other liabilities</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total gross revaluations</strong></td>
<td></td>
</tr>
<tr>
<td>Tax percentage</td>
<td>25.0%</td>
</tr>
<tr>
<td><strong>Total net revaluations</strong></td>
<td>5,707</td>
</tr>
<tr>
<td><strong>Other Revaluations</strong></td>
<td></td>
</tr>
<tr>
<td>i. Goodwill</td>
<td>-</td>
</tr>
<tr>
<td>ii. Participations</td>
<td>-</td>
</tr>
<tr>
<td><strong>Solvency II equity</strong></td>
<td>24,424</td>
</tr>
<tr>
<td><strong>Own fund items</strong></td>
<td></td>
</tr>
<tr>
<td>i. Subordinated liabilities</td>
<td>-</td>
</tr>
<tr>
<td>ii. Foreseeable dividends</td>
<td>-</td>
</tr>
<tr>
<td><strong>Eligible Own Funds Solvency II</strong></td>
<td>24,424</td>
</tr>
</tbody>
</table>

### D.1 Assets

Valuation of most financial assets is based on fair value. In the paragraph below, this valuation methodology is described. For different line items will be referred to this method. In this paragraph line items 1 – 15 from the simplified balance sheet above are described.

#### D.1.1 Fair value measurement

In accordance with the Delegated Regulation, Solvency II figures are based on fair value. In line with the valuation methodology described in article 75 and further of the Solvency II directive and articles 9 and 10, the following three hierarchical levels are used to determine the fair value of financial instruments and non-financial instruments when accounting for assets and liabilities at fair value:

In accordance with the Delegated Regulation, Solvency II figures are based on fair value. In line with the valuation methodology described in article 75 and further of the Solvency II directive and articles 9 and 10, the following three hierarchical levels are used to determine the fair value of financial instruments and non-financial instruments when accounting for assets and liabilities at fair value:
Level 1: Fair value based on quoted prices in an active market
Level 1 includes assets and liabilities whose value is determined by quoted (unadjusted) prices in the primary active market for identical assets or liabilities.

A financial instrument is quoted in an active market if:
- Quoted prices are readily and regularly available (from an exchange, dealer, broker, sector organisation, third party pricing service, or a regulatory body); and
- These prices represent actual and regularly occurring transactions on an arm's length basis.

Financial instruments in this category primarily consist of bonds and equities listed in active markets. Cash and cash equivalents are also included as level 1.

Level 2: Fair value based on observable market data
Determining fair value on the basis of Level 2 involves the use of valuation techniques that use inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is derived from prices of identical or similar assets and liabilities). These observable inputs are obtained from a broker or third party pricing service and include:
- Quoted prices in active markets for similar (not identical) assets or liabilities;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Input variables other than quoted prices observable for the asset or liability. These include interest rates and yield curves observable at commonly quoted intervals, volatility, loss ratio, credit risks and default percentages.

This category primarily includes:
I. Financial instruments: unlisted fixed-interest preference shares and interest rate contracts;
II. Financial instruments: loans and receivables (excluding mortgage loans);
III. Other financial assets and liabilities.

Level 3: Fair value not based on observable market data
The fair value of the level 3 assets and liabilities are determined in whole or in part using a valuation technique based on assumptions that are not supported by prices from observable current market transactions in the same instrument and for which any significant inputs are not based on available observable market data. The financial assets and liabilities in this category are assessed individually.

Valuation techniques are used to the extent that observable inputs are not available. The basic principle of fair value measurement is still to determine a fair, arm's length price. Unobservable inputs therefore reflect management's own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). These inputs are generally based on the available observable data (adjusted for factors that contribute towards the value of the asset) and own source information.

This category primarily includes:
I. Financial instruments: private equity investments (or private equity partners) and real estate equity funds third parties;
II. Financial instruments: loans and receivables – mortgage loans, and mortgage equity funds;
III. Investment property, real estate equity funds associates and buildings for own use;
IV. Financial instruments: asset-backed securities.

D.1.2 Assets per asset category
The balance sheet reports specify different asset categories. In this section, we describe the valuation of each material asset category. The figures correspond to the extended balance sheet which has been reported as QRT S.02.01.

1. Deferred acquisition costs
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

2. Goodwill and Intangible assets
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

1 Not measured at fair value on the balance sheet and for which the fair value is disclosed.
3. Deferred tax
The basis for the DTA / DTL position in the IFRS balance sheet is temporary differences between fiscal and commercial valuation. This DTA / DTL position is the base for this line item on the Solvency II balance sheet, adjusted for Solvency II revaluations, such as revaluation of technical provisions. In accordance with the Delegated Regulation the DTA / DTL position is netted in the balance sheet. The balance sheet of ASR Aanvullende Ziektekostenverzekeringen N.V. contains a DTL.

The deferred tax effects involve a correction related to the fact that (most of) the revaluations as described in this chapter are gross of tax. The tax effect is calculated at 25%.

4. Property plant, and equipment held for own use
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

5. Investments - Property (other than for own use)
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

6. Investments – Equity
Valuation of listed equities is based on the level 1 method of the fair value hierarchy. Unlisted fixed-interest preference shares are valued based on the level 2 method of the fair value hierarchy. The valuation techniques for financial instruments start from present value calculations; derivatives are valued based on forward-pricing and swap models. The observable market data contains yield curves based on company ratings and characteristics of unlisted fixed-interest preference shares. The main non-observable market input for private equity investments is the net asset value of the investment as published by the private equity company (or partner).

Valuation of private equity investments is based on the level 3 method of the fair value hierarchy. The main non-observable market input for private equity investments is the net asset value of the investment as published by the private equity company (or partner).

7. Investments – Bonds
The valuation of these assets is consistent with the IFRS fair value hierarchy as described in paragraph D.1.1.

8. Investments – Derivatives
The valuation of these assets is consistent with the fair value hierarchy as described in paragraph D.1.1. The valuation of listed derivatives is based on the level 1 method of the fair value hierarchy. The valuation of unlisted interest rate contracts is based on the level 2 method of the fair value hierarchy. The valuation techniques for financial instruments start from present value calculations; derivatives are valued based on forward-pricing and swap models. The observable market data contains yield curves based on company ratings and characteristics of unlisted fixed-interest preference shares.

9. Unit-linked investments
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

10. Loans and mortgages
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

11. Reinsurance recoverables
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

12. Cash and cash equivalents
The valuation of cash and cash equivalents is based on the level 1 method of the fair value hierarchy. Cash and cash equivalents include cash in hand, deposits held at call with banks, cash collateral and other short-term highly liquid investments with original maturities of three months or less.

13. Any other assets, not elsewhere shown
The valuation of these assets is based on the IFRS fair value hierarchy as described in paragraph Section D.1.1. Any other assets, not elsewhere shown include insurance and intermediaries receivables, trade receivables and accrued assets.
D.2 Technical provisions

D.2.1 Introduction
In this section, the policies regarding methodology and assumptions for the technical provisions are described. These liabilities arise from insurance contracts issued by ASR Aanvullende Ziektekostenverzekeringen N.V.

D.2.2 Technical provisions methods

D.2.2.1 Medical expense insurance
What follows is a description of the policies, methods and principal assumptions that were decisive in determining the value of the technical provisions and the risk margin.

Composition of homogeneous risk group ASR Aanvullende Ziektekostenverzekeringen N.V.
A homogeneous risk group (HRG) encompasses a collection of policies with similar risk characteristics as stipulated by Solvency II, which are generally recorded separately. In ASR Aanvullende Ziektekostenverzekeringen N.V. coverages are similar over labels and distribution channels. Also, the policies in ASR Aanvullende Ziektekostenverzekeringen N.V. are sold in combination with policies of ASR Basis Ziektekostenverzekeringen N.V. Therefore, also one HRG is defined in ASR Aanvullende Ziektekostenverzekeringen N.V.

Contract boundary
The government decides on the basic health insurance package every year and this package is mandatory for all inhabitants of The Netherlands. The composition of this package may be different from year to year. In addition, the contract boundary of an insurance contract is just one calendar year which is laid down in law. The additional health insurance has also a contract boundary of one year because it is a combination with the basic health insurance. Insured persons are free to accept or reject a new offer from their health insurer after one year. The composition of the portfolio changes mainly because of insured persons switching health insurers. Claims incurred during the period of cover continue to be insurance liabilities for the covering health insurer. The insurance portfolio and hence the risk profile stays stable during one year, because of the breakdown by claim year.

Risk equalisation model
The Dutch Health Insurance is laid down in law (Zvw1) and is supplemented by a risk equalisation model which is performed by the National Health Care Institute (ZINL) for ASR Basis Ziektekostenverzekeringen N.V. This is not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

D.2.2.2 Bases and methods

Best estimate claim provision ASR Aanvullende Ziektekostenverzekeringen N.V.
The inflation method is used for the first months of the new year because little is known about the use of health care and its declaration pattern of the new year. The inflation rate is based on the existing contracts from the previous year which are under negotiation for new year and market rates for health care consumption.

The outstanding claims provisions for additional health insurance are determined using a development factor model in combination with the Bornhuetter-Ferguson method for each claim year at the aggregated level including all health services and products.

For the current claim year, an estimation is made on the basis on an expected loss methodology. Until enough claims are booked to switch to an estimation based on the chain ladder method. In practice, this number of claims is reached by the end of the first half year.

The best estimate claims provision is discounted at the interest rate term structure (zero coupon curve) prescribed by EIOPA. The prevailing yield curve is set internally at group level.

Cash flows
The cash flow pattern of the claim provisions is based on the history of paid claims including expert judgements for the most recent information in a chain ladder model at the level of health type2 aggregated per year and quarter.

---

1 Zvw: Zorgverzekeringswet.
2 For example a health type is: General Practitioner, Pharmacy, Oral Care, Obstetrics, Specialist Medical Care, Paramedical Care, Medical Aids, Patient Transport.
**Best estimate of premium provision ASR Aanvullende Ziektekostenverzekeringen N.V.**

The best estimate for the premium provision is determined using estimated future cash flows from portfolio growth, premium income (only a commercial premium for ASR Aanvullende Ziektekostenverzekeringen N.V.), claims payments and claims handling costs as included in the premium determination and sales results for the new insurance year. This relates to the next 12-month insurance period (one-year contract boundary) and serve as the benchmark for the scale of the premium provision on the reference date.

The cash flow pattern of the future claim provision is based on paid claims in a chain ladder model. The assumptions are:
- Claims received in past months are predictive for the future payment pattern of claims.
- The payment patterns are constant / equal divided for the coming months to year end.
- The payment pattern for the future claims is equal to the payment pattern of the current (already) paid claims.

The same yield curve, which a.s.r. sets internally at group level and subsequently supplied to the supervised entity, is used as for the outstanding claims provisions.

**Claim handling costs ASR Aanvullende Ziektekostenverzekeringen N.V.**

The cash flows for claims handling costs are proportional to the cash flows of the paid claims for the claim provisions. The percentage of claim handling costs is equal to the ratio 'released claims handling costs at the end of year T-1 divided by paid claims including own risk at the end of year T-1 independent of claim years. This fixed percentage is applied to the outstanding claims provision for the current year in the reporting period (t) and for earlier years (t-1, t-2, …, t-n), and to the outstanding claims provision for future years in earlier years. The result is a provision for claims handling costs. The provision for claims handling costs is included in the best estimate for the outstanding claims and premium provisions. The remaining (other) costs are paid uniformly in a year.

**Risk margin methodology**

The insurance risks have been determined in accordance with the standard formula described in the Delegated Regulation. a.s.r. group applies the Cost of Capital method that is applicable to ASR Basis Ziektekostenverzekeringen N.V. and ASR Aanvullende Ziektekostenverzekeringen N.V. as well with a Cost of Capital rate of 6%.

Solvency II describes 4 methods to calculate the risk margin. a.s.r. group has chosen to use the alternative method 1. This method calculates the required future capitals by an approach per risk (sub) module. An approach can of course also be the full calculation of the risk module. The required capital uses the SCR for non-hedgeable risks type 2.

**Impact volatility adjustment**

ASR Aanvullende Ziektekostenverzekeringen N.V. applies the volatility adjustment for discounting cash flows to determine the best estimate and in determining the Required Capitals for the SCR. In the next table the impact is shown of this volatility adjustment on the financial position and own funds of ASR Aanvullende Ziektekostenverzekeringen N.V.

<table>
<thead>
<tr>
<th>Impact of applying VA = 0 bps</th>
<th>24</th>
<th>VA = 4 bps</th>
<th>VA = 0 bps</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>31 December 2019</td>
<td>31 December 2018</td>
<td>31 December 2019</td>
<td>31 December 2018</td>
</tr>
<tr>
<td>TP</td>
<td>-2,061</td>
<td>2,179</td>
<td>-2,065</td>
<td>2,196</td>
</tr>
<tr>
<td>SCR</td>
<td>14,088</td>
<td>13,425</td>
<td>14,089</td>
<td>13,426</td>
</tr>
<tr>
<td>MCR</td>
<td>3,522</td>
<td>3,468</td>
<td>3,522</td>
<td>3,469</td>
</tr>
<tr>
<td>Basic own funds (total)</td>
<td>24,424</td>
<td>26,317</td>
<td>24,427</td>
<td>26,305</td>
</tr>
<tr>
<td>Eligible own funds</td>
<td>24,424</td>
<td>26,317</td>
<td>24,427</td>
<td>26,305</td>
</tr>
</tbody>
</table>

Table: impact of applying VA = 0 bps

**D.2.3 Level of uncertainty**

This paragraph contains a description of group policy, which is applicable for the solo entity. a.s.r. distinguishes between two sources of uncertainty with regard to the level of the technical provisions. These sources are model risk and process risk. The uncertainty associated with these risks has been mitigated as described below.
Process risk
The process risk is mitigated using the Risico Control Matrix (RCM), which creates a reasonable degree of assurance as to the reliability of financial reports. Key controls have been identified and to a larger extend implemented for the calculation process. In addition, the effectiveness of the RCM is verified by an independent party and supplementary checks are performed where needed. As part of RCM or the additional checks, the four-eye principle has demonstrably been applied to the calculation of the technical provision.

Model risk
The second risk that a.s.r. has identified in relation to the technical provisions is model risk. Regular procedures have provided adequate certainty with regard to this risk. To illustrate, a model validation process mitigates the risk of material misstatements or that key facts have been omitted. In addition, FRM, in its role as the second line of defense, performs an independent internal review of the technical provisions as described in the previous phase.

D.2.4 Reinsurance and special purpose vehicles (SPVs)
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

D.2.5 Technical provisions
In this table a reconciliation is made between the Solvency II and the IFRS valuation of provisions. Solvency figures are part of the balance sheet S.02.01. The next paragraph describes a brief explanation of these differences.

<table>
<thead>
<tr>
<th>Technical provisions: IFRS versus Solvency II</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 December 2019</td>
</tr>
<tr>
<td>Similar to non-life</td>
</tr>
<tr>
<td>Best estimate</td>
</tr>
<tr>
<td>Risk margin</td>
</tr>
<tr>
<td>Technical provision</td>
</tr>
</tbody>
</table>

D.2.6 Reconciliation between IFRS and Solvency II
Under Solvency II, the technical provisions are calculated using a different method compared to IFRS. In this section the reconciliation between IFRS and Solvency II is described per business line.

Similar to Non-life
The revaluation for Similar to Non-life (medical expense) is caused by:
- The IFRS LAT margin: -€ 7,609 thousand.

The technical provisions under IFRS contains a prudence margin of 22.7%.

D.3 Other liabilities

D.3.1 Valuation of other liabilities
In line with the valuation of assets, the accounting principles for other liabilities used in the Pillar III reports are generally also based on the IFRS as adopted by the EU. Any differences between the valuation methods for IFRS and Solvency II purposes are addressed in detail per liability category. In this paragraph line items 18-21 from the simplified balance-sheet above are described.

18. Pension benefit obligations
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

On group level a.s.r. has a number of defined benefit plans for own staff in place. Current service costs for the OTSO’s are included in operating expenses.

19. Deferred tax liabilities
See 3. Deferred tax assets.
20. **Subordinated liabilities**
In IFRS the perpetual hybrid loans are classified as equity as there is no requirement to settle the obligation in cash or another financial asset or to exchange financial assets or financial liabilities under conditions that are potentially unfavourable for ASR Aanvullende Ziektekostenverzekeringen N.V.
According to IFRS, the perpetual hybrid loans are measured at amortized cost. For the purpose of Solvency II, they are both measured at fair value.

Directed by the regulator in Solvency reporting the perpetual hybrid loans are classified as subordinated liabilities.

21. **Other liabilities**
Other Liabilities contains different small line items:

* **Insurance and Intermediaries payables**
The valuation of these liabilities follows the Solvency II fair value hierarchy as described in paragraph D.1.1 This category is subject to the same valuation as the asset category Cash and Cash equivalents.

* **Trade payables (non-insurance)**
The valuation of these liabilities follows the Solvency II fair value hierarchy as described in paragraph D.1.1 This category is subject to the same valuation as the asset category receivables.

* **Any other liabilities not disclosed elsewhere**
The valuation of these liabilities follows the Solvency II fair value hierarchy as described in paragraph D.1.1. This item consists primarily of tax payables.

* **Contingent liabilities**
Contingent liabilities are defined as:
a possible obligation depending on whether some uncertain future event occurs, or
a present obligation but payment is not probable or the amount cannot be measured reliably.

Contingent liabilities are recognised on the IFRS balance sheet if there is a probability of >50% that the contingent liability leads to an “outflow of resources”. These liabilities are also recognised on the Solvency II balance sheet.

Solvency II prescribes that all contingent liabilities be recognised on the Solvency II balance sheet. This covers cases where the amount cannot be measured reliably or when the probability is <50%. For these cases, a regular process is in place to determine whether contingent liabilities should be recognized on the Solvency II balance sheet.

The ASR Aanvullende Ziektekostenverzekeringen N.V. solvency ratio does not include contingent liabilities.

D.3.2 **Reconciliation from Solvency II equity to EOF**
The differences described in the above sections are the basis for the reconciliation of IFRS equity to equity Solvency II.
To reconcile from Solvency II Equity to EOF, the following movements are taken into consideration:

* **Subordinated liabilities**
In accordance with the Delegated Regulation the subordinated liabilities are part of the EOF. Further information of this liabilities is described in section E.

* **Foreseeable dividends and distributions**
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

* **Deductions for participations in financial and credit institutions**
Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.

* **Tier 3 Limitations**
In accordance with the Delegated Regulation EOF is divided in tiering components. There are boundary conditions related to the size of these components. Excess of this limits results in capping of EOF. For ASR Aanvullende Ziektekostenverzekeringen N.V. capping does not apply per Q4 2019.
D.4 Alternative methods for valuation

ASR Aanvullende Ziektekostenverzekeringen N.V. does not apply alternative methods for valuation.

D.5 Any other information

Not applicable for ASR Aanvullende Ziektekostenverzekeringen N.V.
E Capital management

Key figures

Eligible own fund

<table>
<thead>
<tr>
<th>Tier 1 capital - unrestricted</th>
<th>Tier 1 capital - restricted</th>
<th>Tier 2 capital</th>
<th>Tier 3 capital</th>
<th>Eligible own funds to meet SCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>24,424</td>
<td>24,424</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>26,317</td>
<td>26,317</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The solvency capital requirement is build up as follows:

<table>
<thead>
<tr>
<th>Market</th>
<th>Insurance</th>
<th>Counter-party</th>
<th>Operational</th>
<th>Diversification</th>
<th>LAC DT</th>
<th>SCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>12,221</td>
<td>399</td>
<td>-1,441</td>
<td>-935</td>
<td></td>
<td>14,088</td>
</tr>
<tr>
<td></td>
<td>2,163</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>11,503</td>
<td>202</td>
<td>-1,377</td>
<td>-892</td>
<td></td>
<td>13,425</td>
</tr>
<tr>
<td></td>
<td>2,175</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The solvency ratio stood at 173% as per 31 December 2019 based on the standard formula as a result of € 24,424 thousand EOF and € 14,088 thousand SCR.
E.1 Own funds

E.1.1 Capital management objectives

Management

Overall capital management is administered at group level. a.s.r. currently plans to consider investing capital above the Solvency II ratio (calculated based on the standard formula) of 160% (management threshold level) with the objective of creating value for its shareholders. If and when a.s.r. operates at a level considerably above the management threshold level and it believes that it cannot invest this capital in value-creating opportunities for a prolonged period of time, it may decide to return (part of this) capital to shareholders. If a.s.r. chooses to return capital, it plans to do so in a form that is efficient for shareholders at that time. a.s.r. actively manages its in-force business, which is expected to result in free capital generation over time. Additionally, business improvement and balance sheet restructuring should improve the capital generation capacity while advancing the risk profile of the company. The legal entities are individually capitalised and excess capital over management’s targets for the legal entities is intended to be up-streamed to the holding company as far as is needed for amongst others covering external dividend, coupon payments on hyrbids/senior financing instruments and holding costs and in so far the local regulations and the internal risk appetite statement allow.

Objectives

The group is committed to maintain a strong capital position in order to be a robust and sustainable insurer for its policyholders and other stakeholders. The objective is to maintain a solvency ratio well above the minimum levels as defined in the risk appetite statements and above the relevant management threshold levels. Sensitivities are periodically performed for principal risks and annual stress tests are performed to test a.s.r.’s robustness to withstand moderate to severe scenarios. An additional objective is to achieve a combination of a capital position and a risk profile that is at least in line with a “single A” rating by Standard & Poor’s.

The SCR is reported on a quarterly basis and proxies are made on both a monthly and weekly basis. The internal minimum solvency ratio for ASR Aanvullende Ziektekostenverzekeringen N.V. as formulated in the risk appetite statement is 110%. The lower limit solvency target is 130%. The management threshold level for the solvency ratio is above 150%. The solvency ratio stood at 173% at 31 December 2019, which was comfortably above the internal requirement of 110% and the management threshold level of 150%.

In accordance with a.s.r.’s dividend policy, the liquidity of the underlying entities is not taken into account for the liquidity position of the group. However, the capital is recognised in the capital position of the group, since a.s.r. has the ability to realise the capital of this OTSO, for example by selling the entity.

If ASR Aanvullende Ziektekostenverzekeringen N.V. elects to return capital, it intends to do so in the form that is efficient for shareholders at that time. In 2019, € 9 million dividend upstream has taken place.

The table below shows how the eligible own funds of ASR Aanvullende Ziektekostenverzekeringen N.V. relate to the different capital targets.
The table below details the capital position of ASR Aanvullende Ziektekostenverzekeringen N.V. as at the dates indicated. With respect to the capital position, Solvency II requires the insurers to categorize own funds into the following three tiers with differing qualifications as eligible available regulatory capital:

- **Tier 1 capital** consists of Ordinary Share Capital and Reconciliation reserve.
- **Tier 2 capital** consists of ancillary own funds and basic Tier 2. Ancillary own funds consist of items other than basic own funds which can be called up to absorb losses. Ancillary own fund items require the prior approval of the supervisory authority. ASR Aanvullende Ziektekostenverzekeringen N.V. has no ancillary own fund items.
- **Tier 3 consists of Deferred tax assets.**

The rules impose limits on the amount of each tier that can be held to cover capital requirements with the aim of ensuring that the items will be available if needed to absorb any losses that might arise.

### Eligible Own Funds to meet the SCR

<table>
<thead>
<tr>
<th></th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1 capital - unrestricted</td>
<td>24,424</td>
<td>26,317</td>
</tr>
<tr>
<td>Tier 1 capital - restricted</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tier 2 capital</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tier 3 capital</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Eligible own funds to meet SCR</strong></td>
<td>24,424</td>
<td>26,317</td>
</tr>
</tbody>
</table>

### E.1.3 Own funds versus MCR

The MCR calculation is based on the standard formula.

### Eligible Own Funds to meet the MCR

<table>
<thead>
<tr>
<th></th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1 capital - unrestricted</td>
<td>24,424</td>
<td>26,317</td>
</tr>
<tr>
<td>Tier 1 capital - restricted</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tier 2 capital</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tier 3 capital</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Eligible own funds to meet MCR</strong></td>
<td>24,424</td>
<td>26,317</td>
</tr>
</tbody>
</table>

The eligible own funds to meet the MCR equal the eligible own funds to meet the SCR, as there is no Tier 2 and Tier 3 capital.

According to Delegated Regulation article 248 to 251 the MCR (€ 3,522 thousand) of ASR Aanvullende Ziektekostenverzekeringen N.V. is calculated as a linear function of premiums, technical provisions and capital at risk.
E.1.4 Description of grandfathering
ASR Aanvullende Ziektekostenverzekeringen N.V. has not issued any hybrid loans.

E.2 Solvency Capital Requirement

Capital requirement
The required capital stood at €14,088 thousand per 31 December 2019. The required capital (before diversification) consists for €1,681 thousand out of market risk and the insurance risk amounted to €12,221 thousand as per 31 December 2019.

ASR Aanvullende Ziektekostenverzekeringen N.V. complied during 2019 with the applicable externally imposed capital requirement. The table below presents the solvency ratio as at the date indicated.

<table>
<thead>
<tr>
<th>Eligible own funds to meet the SCR</th>
<th>31 December 2019</th>
<th>31 December 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible Own Funds Solvency II</td>
<td>24,424</td>
<td>26,317</td>
</tr>
<tr>
<td>Required capital</td>
<td>14,088</td>
<td>13,425</td>
</tr>
<tr>
<td>Solvency II ratio</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>173%</td>
<td>196%</td>
</tr>
</tbody>
</table>

Under Solvency II it is permitted to reduce the required capital with the mitigating tax effects resulting from a 1-in-200-year loss (“Shock loss”). There is a mitigating tax effect to the extent that the Shock loss (BSCR + Operational risk) is deductible for tax purposes and can be compensated with taxable profits. This positive tax effect can only be taken into account when sufficiently substantiated (‘more likely than not’). a.s.r. included a beneficial effect on its solvency ratio(s) due to the application of the LAC DT. The LAC DT benefit is €935 thousand.

Relevant regulation and current guidance (Delegated Regulation, Level 3 guidelines, Dutch Central Bank Q&As and IAS12) is taken into account in the development of the LAC DT methodology.

E.3 Use of standard equity risk sub-module in calculation of Solvency Capital Requirement
The transitional measure for equity risk applies for shares in portfolio at 01-01-2016. The SCR equity shock is 22% at 01-01-2016, and linear increasing to (i) 39% + symmetric adjustment for type I shares and (ii) 49% + symmetric adjustment for type II shares.

E.4 Differences between Standard Formula and internal models
a.s.r. solvency is governed by a standard formula, rather than the self-developed internal model. The EB believes that this should enhance transparency and consistent interpretation.

E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement
As ASR Aanvullende Ziektekostenverzekeringen N.V. has not faced any form of non-compliance with the Minimum Capital Requirement or significant non-compliance with the Solvency Capital Requirement during the reporting period or at the reporting date, no further information is included here.